vaccine-preventable Public public subject free whole possible current individual such assert subsequent additional digital re-hosted educational non-commercial computer-extracted scanned Computer-extracted such unusual odd Original 2021-11-05 Vaccine-Preventable * wº- º ~ * * * –- + responsible additional website Vaccine-Preventable commercial non-CDC responsible URL current upper human critical first Greek epidemic other 5th medical Vaccine-Preventable l General Other Essential Clinical laboratory Clinical º first epidemic Other latin laboratory Clinical Secular Other Clinical laboratory Adverse … º- first first live bacterial wiral human im Clinical laboratory Clinical laboratory Clinical laboratory Adverse Waccine =- º * whole-cell first live tetanus t- nvirº slinké lable Clinical Clinical laboratory Special Clinical laboratory isºlated viral first influenza human laboratory Other Clinical Antiviral developed oral smallpox global lable Pneumococcal laboratory Meningococcal Clinical laboratory .278 Clinical Last indigenous virus Clinical laboratory A-2 2005-2006 Immunocompromised irst recombinant Two-dose civilian lable C-1 Federal ............................... E-1 Reportable Waccine-Preventable 1950-2003 ............ 20th 1962-2004 ................ 272:1133-7 Acellular rotavirus I-1 |-2 |-3 |-4 |-5 |-6 local lusive inactivated vaccine Related current acellular single-dose Tetanus.acellular single acellular single-dose vial acellular sanofi single-dose acellular single-dose symge single-dose vial sanof single-dose generic 15-dose vial acellular single-dose acellular sanofi single-dose 10-dose vial generic 15-dose vial immune -T single-dose influenzae single-dose – single-dose single-dose vial single-dose vial single-dose single-dose | immune single-dose single-dose Hepatts single-dose single-dose single-dose vial single-dose | trivalent influenza single-dose live influenza single-dose 10-dose vial sanofi 10-dose vial sanoſ single-dose single-dose single-dose vial single-dose vial | single-dose vial single-dose single-dose —- pasteur single-dose Meningococcal single-dose Pneumococcal 7-valent single-dose – 23-valent single-dose vial 5-dose vial sanoſ single-dose 10-dose single-dose – | untvia's | multi-dose | Japanese _|_JE-VAX sanoſ single-dose vial single-dose single-dose single-dose 20-dose live oral | 4-capsule YF-Vax pasteur 5-dose vial 521-7468 • s * Vaccine-Preventable complicated detailed basic useful Many excellent available additional —- human indigenous “ —- foreign “ discriminatory nonself infectious –- infectious most foreign –- * specific single specific single —- related basic * active passive —- _-r p own —- permanent Active own _- animal human human Passive Passive effective • i Temporary few complex y primary foreign “ nticien live such capable immune immune ifi specific cell-mediated foreign effective live alive immune such Other such long certain effective immune good i other important human immune Homologous human other Passive temporary common passive last full-term same certain red small e.g. intravenous immune large whole red major human homologous pooled homologous human heterologous human immune many different many different Homologous human antibody high specific donated high other lesser several Heterologous available serum human polyclonal many different immortalize single antibody-producing single monoclonal specific single single related related certain infectious many certain colorectal ovarian chronic lymphocytic non-Hodgkin transplant infectious available respiratory syncytial • human – human other other other humanized specific other – monoclonal antigen-specific cellular passive temporary active many • immunologic similar natural active natural general infectious lifelong many immunologic certain many active immune similar natural potential immunologic similar natural — viral bacterial protein-based polysaccharide-based wild effective similar natural effective more similar better immune Many maternal aluminum-containing such nutritional basic live live inactivated different “ vaccine live available live bacterial available whole Fractional protein-based polysaccharide-based bacterial Most polysaccharide-based potent wild serial tissue wild vaccine m * º-º- ºr- * vaccinated small immune live ineffective live such wild live attenuated “ much milder natural adverse immune live attenuated identical natural immune weakened wild effective severe fatal uncontrolled only e.g. certain human live attenuated original disease-causing live oral Active live attenuated possible transplacental poor n vaccine sensitive least affected fragile available live viral yellow Oral live • i available yellow new live bacterial bacille i oral oral available immune fractional polysac- live 3-5 humoral alive entire immunodeficient affected live present e.g. antibody-containing multiple general first protective protective second third natural immune inactivated humoral cellular diminish inactivated periodic supplemental available available inactivated whole viral whole whole bacterial available Fractional acellular available human available acellular available united unique inactivated long certain available pneumococcal meningococcal pure available pneumococcal meningococcal pneumococcal meningococcal immune pure independent able immunogenic T-cell—independent includi polysaccharide less functional younger • most inactivated “ polysaccharide less functional polysaccharide little late immune independent multiple first conjugated pneumococcal meningococcal Recombinant genetic recombinant available pure Live Salmonella influenza thorough common more American current revised familiar print important appropriate Specific antibody-containing live simultaneous nonsimultaneous different subsequent same immune same Simultaneous immune antibody-containing live Simultaneous nonsimultaneous different subsequent same certain such immune parenteral vaccine live parenteral i enough viral live necessary least less necessary necessary antibody-containing live varicella low anti-Rho postpartum rubella-susceptible other last possible necessary yellow immune few immune significant live influenza other available respiratory syncytial young intravenous human RSV-IG other human live parenteral only monoclonal syncytial simultaneous Simultaneous Monsimultaneous live inactivated decreased adverse Simultaneous eligible important appropriate early unvaccinated vaccine-eligible same Individual same sanofi-pasteur same Nonsimultaneous i vaccine different Live live influenza live least i other live parenteral less second effective serologic serologic yellow i less single-antigen yellow live parenteral live influenza second • yellow oral oral oral other other Oral younger available likely same yellow live live oral oral Live oral live parenteral other inactivated live inactivated other multidose multidose youngest Most more adequate same optimal best Table minimal minimal inter- recommended ºn -aº * multidose shorter recommended necessary up-to-date international accelerated minimum minimum interval Accelerated less minimal earlier minimal first younger older second consid- few minimum unlikely negative immune less recommended ear minimum reliable preferable reliable e.g. preferable minimum valid 4-day unique earlier minimum valid invalid greater recommended minimum interval Table certain local specific 4-day scheduled next available routinely recom- less recommended minimum earlier minimum minimum valid earlier minimum Available extended significant final necessary extended necessary add extended only oral typhoid oral four-dose more long-lasting single multiple periodic live injected first recommended additional single second immune second “ live long-lasting necessary inactivated first recommended protective second third inactivated few notable periodic additional protective rare older immunologic long | active specific adverse untoward extraneous primary Adverse vaccine adverse adverse adverse true coincidental further extraneous side true adverse coincidental general least severe most frequent Allergic severe least frequent common adverse local i such accine adverse Local * Local common inactivated – common inactivated such mild self-limited rare local exaggerated severe due high local systemic Local Local adverse few mild self-limited many Systemic adverse generalized common nonspecific vaccinated unrelated concomitant viral nonspecific unrelated adverse frequent whole-cell com- systemic adverse common inactivated acellular adverse live adverse such • ly similar mild natural due component – rare serious adverse adverse live mild mucous nose upper influenza-like third vaccine adverse severe anaphylactic allergic allergic other such antibiotic bacterial allergic life- rare less allergic good prior public private significant adverse significant adverse unsure adverse dictate Most temporary later serious adverse adverse * General serious general present similar serious adverse adverse such * less general present adverse high acellular subsequent pediatric high e.g. adverse Permanent few true severe allergic permanent severe anaphylactic prior dose vaccine prior •encephalopathy due due identifiable identifiable ºwithin vacci permanent further pediatric pertussis-containing greater shock-like hypotonic persistent inconsolable more temporary live i temporary severe recent antibody-containing * true anaphylactic | eneral severe anaphylactic allergic subsequent Severe medical severe allergic urticaria appropriate rare table allergic animal common animal egg yellow influenza able anaphylactic anaphylactic-like adverse reasonable yellow influenza Several severe chick allergic severe Egg-allergic prior trace anaphylactic Most neomycin allergy delayed-type cell-mediated delayed-type liquid commercial responsible allergic natural dry natural natural natural same lesser Natural medical other * * _ natural vial intravascular Synthetic synthetic medical vial Synthetic synthetic natural natural allergic common latex contact-type type prolonged latex-containing injection-procedure—associated latex diabetic Allergic rare allergic severe severe anaphylactic natural allergic latex other anaphylactic dry natural natural pregnant theoretical fetal theoretical pregnant fetal pregnant Susceptible pregnant eligible severe fatal immunosuppressed due uncontrolled oral immunosuppressed live isolated safe immunosuppressed • > alternate-day short topical significant immunosup- congenital generalized live immunosuppressed immunosuppressed same live Live least large live more prednisone daily more weight longer such alternate-day short less high-dose topical physiologic live recombinant human immune therapeutic monoclonal anti-tumor latent other opportunistic live prudent live least suppressed poor functional immune immunosuppressed Additional immunosuppressed human immuno- general same other Live-virus inactivated I- * severe varicella asymptomatic immunosup- severe due Susceptible inactivated hematopoietic bone neoplastic congenital own autologous other transplant vaccine-preventable type autologous certain vaccine- preventable transplanted inactivated influenza immunocompetent meningococcal pneumococcal insufficient other close healthcare vaccinated available peripheral umbilical allogeneic • annual • immunocompetent meningococcal insufficient |General concurrent vaccine adverse adverse ill moderate severe live inactivated common such upper NOT Invalid invalid certain true • Such * * invalid • common invalid minor * Non-vaccine-related • unrelated anaphylactic certain Minor invalidiºm.ation- mild acute such low-grade upper mild Several large young small i and/or multiple subsequent large earlier small increased adverse minor such mild Low-grade necessary ill. immune antibiotic antiviral live-virus ſ lº tic ſ ill adverse critical healthy pregnant immunosuppressed healthy pregnant immunosuppressed Most live household pregnant immunosuppressed pregnant immunosuppressed influenza immunosuppressed protected lesser noncommu- nicable human common most older immunosuppressed immune eligible low passive vaccine-preventable maternal chronological decreased certain low less chronological initial gestational likely older larger unknown hepati- less initial count- ed additional optimal first premature HBs.Ag-negative less first chronological chronological stable consistent Non-Vaccine-Related nonspecific allergy available duck Nonanaphylactic such true Nonanaphylactic only relevant adverse sudden infant hereditary first-degree immune potential same skin most m false-negative same more most routine skin skin available such available prudent serious adverse Effective difficult few child acute necessary severe allergic more time-efficient generic specific Most familiar minor allergic medical last open-ended allergic previous additional such high hypotonic immune immunodefi- oral • last immune i healthy immunosuppressed immune last last immune live passive last few unreported earlier pregnant pregnant pregnant pregnant Active passive Red American recom- American immune altered m opportunistic hematopoietic Infectious American Potential Simultaneous | important public safe efficacious important appropriate essential eligible recommended high own Vaccine-preventable lowest wild-type continued vaccine-preventable low several possible new suboptimal sustainable crucial vaccine-preventable unprotected other such severe social economic physical sick miss healthcare many ultimate late better º • optimal • * Sustainable Specific further following Childhood suboptimal other lower older influenza past pneumococcal racial Low-income greater underim- “ inner varicella vac- second influenza low healthcare important fewer healthcare influenza adult consistent influenza older Cost-effectiveness more More least Sustainable High one-time short-term necessary lasting effective Many such other proven specific such low → * successful current present most sufficient least healthcare unvaccinated up-to-date necessary high other low knowledgeable concerned capable new public private diagnostic high public private governmental nongovernmental medical professional trained other healthcare specific effective high sustainable specific measurable Second key governmental Special • • advanced personal medical defined potential awareness necessary behavior appropriate unique advanced personal Much personal critical lasting medical defined targeted essential several most healthcare accurate own actual subsequent flexible assessment “ more defined necessary behavior representative appropriate next second same summary specific e.g. missed substantial effective focused personal critical desired sufficient high desirable variable effective single different different small longer-term new Professional other Many other possible diverse final more own cov- other • more individual • * successful other knowledgeable appropriate statistical educational Staff educational other such informal local structured professional actual such electronic different face-to-face e-mail cost-saving fast WFC-AFX last several public private Many federal other available periodic possible single avoid overall single more private vaccine large private Comprehensive enable electronic previous previous basic individual • * patient immediate further various potential such missed specific such patient further available Comprehensive Additional available effective Many gradual consistent private substantial median up-to-date public private state- public private Healthy past annual widespread childhood powerful Other substantial certain other immu- High complementary * i favorable • missed • vital medical electronic critical optimal applicable legal specific such available available easy easy accurate i accurate active medical —reflect current up-to-date new complete more necessary complete accurate School-based public community-based primary quick reliable such important new alternative available = patient population-based computerized geographic complete medical single multiple reliable enrolled accurate additional immuniza- individual geographic younger operational population-based age-group federal local key federal More available powerful recom- pediatric likely vaccine reluctant likely positive true many necessary useful next additional Reliable —powerful likely -verbal upcoming verbal higher recommended due due past due past due e.g. effective effective various * available computer-generated weekly specific other preventive other recommended aggressive upcoming recall overdue local technical recall public private * routine due past due due past due different “ overall ºt- — “ computer-generated clinic past due m T- _-_-_ such “ “ nurse continual Missed missed healthcare eligible Missed Missed several many simultaneous injectable immune adverse parental scientific unaware available invalid more missed larger well-child vaccinating Other large institutional bureaucratic such acute-care missed Several missed missed many different following • nonphysician direct physician such other positive º eligible simultaneous additional clinic Missed • responsible knowledgeable responsible higher general Numerous educational available professional greater • recall reminder effective missed other knowledgeable valid additional appropriate immu- unknown physical psychological Physical such * Psychological inconvenient clinic —unpleasant long specific patient such clinic many possible knowledgeable such eligible Psychological subtle important Unpleasant r- * = a- clinic needed | such knowl- interpersonal updated reliable direct accurate supportive encouraging critical American Programmatic —assessment provider-based American American high public public clinic cover- underimmunized cost-effective underimmunized private adolescent adult Available preventive Available simulated reg- prime general Further precau- individual such potential adverse specific significant public pharmaceutical safe effective adverse minor self-limited rare serious following key active ongoing vaccine-preventable longer same adverse true adverse current vaccine-preventable likely adverse reportable vaccine-preventable public public critical whole-cell decreased epidemic increased vaccine Public critical higher healthy lower rare sound several other similar willing Close timely suspected vaccine adverse true coincidental unrelated public higher other medical pharmaceutical curative healthy Public adverse healthy healthy lower sick lower possible rare adverse public many local widespread potential large universal human-directed strict regulatory Sound dynamic necessary adjust oral global routine actual global inactivated Sound ongoing continuous other pharmaceutical undergo extensive phased human clinical clinical serious few last best right last several few several already-licensed adverse serious safe effective clinical rigorous potential outweigh common such injection-site small rare many largest more inadequate vaccine's possible rare essential vaccine-associated adverse public Fundamental public Good undergo own public • Common * known rare unusual • limited Large-Linked healthcare new rare known patient Additional adverse rare delayed postlicensure criti- cal rare known particular vaccine high certain possible adverse further current postlicensure public possi- ble rare identified large-linked rare specific vol- long-term unanswered clinical Most clinical vaccine individual healthcare certain adverse specific national significant adverse passive general local public more total large small past additional significant medical certain vaccine healthcare local unknown adverse Serious adverse life-threatening permanent serious additional medical full possible serious follow-up strict able primary new rare vaccine adverse known patient particular adverse intussuscep- anaphylactic Additional adverse detailed personal available 800-553-6847 Adverse common rare local systemic pre- intrinsic faulty recent adverse • Vaccine-induced Due intrinsic individual e.g. vaccine-associated paralytic • Vaccine-potentiated febrile predisposed • Due technical • reported due natural More adverse more plausible adverse particular specific clinical strong biologic e.g. anaphylaxis natural skin “ positive controlled clinical greater specific adverse vaccinated unvaccinated adverse other Large-Linked potential passive further Such stud- informative costly time-consuming assess- single licensed severe passive clear causal vaccine adverse high- active large-linked large computerized computerized medical such single-provider routine such comple- vaccine adverse passive economical rapid postlicensure medical more approxi- various Further available Clinical recent Clinical scientific vaccine indi- vidual certain adverse better such similar regional infor- clinical coordinated vaccine individual patient vaccine more Large-linked vaccine individual adverse better * prominent whole-cell Legal scientific vaccine • i several recommended vacci d public concerned epidemic public certain “ ” “ adverse medical serious adverse certain unrelated more available vaccine more effective rare adverse Further available federal • f key proper contraindica- i vaccine side º Further available resource other best possible Other vaccine suspected —vaccine vaccine vaccine oldest expira- prescribed prior administra- same vaccine corrective public More available available important appropriate optimal same more spe- minimum • same important effective greater adverse serious adverse adverse • Invalid local prior dose vaccine unrelated medical such separated more higher such pediatric Good careful patient extra serious adverse general present adverse present Most temporary later More individual allergic American key serious adverse Many most e.g. diarrhea minor upper otitis low-grade local low-grade moderate prior antimicrobial infectious lººk- utted unºſº atº lizatiº | reſ ſ • unrelated best clinical specific suspected vaccine Allergic anaphylactic available immediate familiar cardiopulmonary Suspected certain adverse sure reportable available secure 877-721-0366 20849-1 one-page 877-721-0366 vaccine valuable ongoing safest rare private available multiple legal understandable sound medical vaccine “ public private available responsible other available certain Further few certain religious personal basic vaccine devel- effective vaccine imperative specific accurate more extensive up-to-date //www.cdc.gov/nip/menus/vacc patient healthcare factual appropriate empathetic essential misinfor- vaccine Safe available helpful effective public common key unimmunized unimmunized certain potential vaccine-preventable unimmunized critical American Red American permanent adverse current future new vaccine m toxin-mediated • Greek leather 5th i 6th 5th i diphtheritic 6th • late y aerobic gram-positive specific gram-positive genetic tox toxigenic severe tox distinguished selective normal diphtheroid other nor- e.g. severe Susceptible toxigenic cellular responsible local responsible major low Clinical non-toxin-producing rare severe toxigenic inadequate • 2-5 1-10 mucous mucous clinical tonsillar convenient —genital anterior nasal indistinguishable common blood-tinged white nasal apparent poor systemic antibiotic common substantial systemic exudative 2-3 insidious Early low-grade bluish-white small * high most soft patient greyish-green black minimal adherent forcible Extensive respiratory enough severe rapid high toxic severe marked submandibular anterior lymphadenopathy characteristic pharyngeal barking Cutaneous cutaneous homeless common responsible high natural popu- chronic other m recent nontoxigenic skin toxigenic less other toxigenic nontoxigenic Other mucous vulvovaginal external Most attributable local frequent abnormal cardiac early fatal motor soft frequent third fifth Secondary respiratory diaphragmatic Other otitis due overall higher younger older little last Laboratory clinical imperative presumptive critical pharyngeal discolored tonsillar selective local Most attributable Most common respiratory hemolytic helpful i clinical multiple Chinese Other direct clinical diagnostic prior antibiotic positive suspect presumptive close low nonprotective less commercial several Medical i available Investigational unbound available 404-639-8257 other suspected adequate provisional clinical appropriate Respiratory airway erythromycin maximum procaine less more contagious consecutive negative Preventive close household younger old old older 7- 10-day oral close first cutaneous non- clinical prevalent highest highest significant Native geographic asymptomatic high transient person-to-person skin infected * asymptomatic several i variable pres- less more Chronic more Effective antibiotic Secular major 1940-2004 top i younger rapid widespread late high cutaneous nontoxigenic cutaneous most lower 1980-2004 known older older Most unimmunized immunized current inadequate 1980-2004 many less protective rare endemic Native 5-14 15-24 25-39 40-64 toxigenic m infected classic toxigenic good other major former epidemic More more more entire epidemic due several routine early early toxigenic liquid Single-antigen available available pediatric acellular available combined DTaP-inactivated more Pediatric similar much younger pediatric older adult pediatric available— 5-12.5 pediatric older 11-64 • * primary protective greater more clinical acellular usual primary Primary first Primary whºs whºs Primary 15-18 mos third fourth third less valid pediatric younger old first primary ~12 older first third second primary primary fourth fourth fifth recom- fourth fourth Routine last most optimal last first least last dose next frequent local adverse Routine Unvaccinated older primary prior rimary diphtheria-containing Primary Primary 6-12 more unvaccinated older first primary first least third dose second first single unvaccinated older more recommended subsequent active diphtheria Adverse erythema common Local self-limited palpable several other systemic common Exaggerated local diphtheria- tetanus-containing extensive painful shoulder frequent severe high further severe local prior severe systemic such generalized neurologic severe allergic prior additional local systemic common systemic allergic prior severe acute minor additional pediatric Suspect suspect cutaneous toxigenic following toxigenic appropriate preliminary clinical epidemiologic early presumptive strict least negative close household other oral close nasal antibiotic immunized fewer unknown immediate pri- mary current more diphtheria toxoid-containing recent Other younger Unimmunized adequate antibiotic additional 10-day follow-up first other preventive acellular young Provisional available //www.cdc.gov/nip/recs/provisional_recs/default.htm Fatal due Bacterial vaccine- preventable former pandemic fatal character- generalized convulsive skeletal 5th clinical fatal human same human specific protective passive gram-positive anaerobic drumstick sensitive resistant usual resistant other Manure-treated large agricultural significant human contaminated tetani clinical potent minimum human nanograms 70-kg * * gram-positive spore- animal human ng/kg central nervous • neurotransmitter unopposed 3-21 clinical local common cephalic rare common spasms 3-4 complete newborn protective passive anaerobic low several central nervous peripheral spinal sympathetic nervous typical clinical neuro- unopposed autonomic nervous Clinical general further central nervous longer shorter higher neonatal clinical different Local uncommon persistent same anatomic many Local generalized fatal rare otitis ear present middle cranial facial common first trismus abdominal Other elevated episodic rapid last several Complete Neonatal generalized newborn Neonatal protective passive immune unhealed umbilical unsterile Neonatal common developing more rare vocal long sustained autonomic nervous abnormal Nosocomial common prolonged Secondary hospital-acquired Pulmonary elderly common late autopsied recent fatal likely fatal older unvaccinated tetanus obvious direct Laboratory laboratory clinical bacteriologic demon- Medical Necrotic foreign tetanic supportive adequate critical immune unbound single Intravenous immune tetanus available Pulmonary extreme tetanus other x10 last dose * last dose * contagious Active practical useful proper important active passive con- documented primary tetanus clean minor prior uncertain prior early temporary protective most encoun- populated hot damp organic intestinal apparent major minor recent higher minor severe likely elective deep ear dental contagious only vaccine-preventable infectious contagious 1947-2004 marked early late late routine notifiable tetanus ~0.05 recent all-time 1980-2004 reported older younger younger last younger 1980-2003 younger older younger young injection-drug late primary high i rare recent available acute Tetanus—1998-2000 available other * frequent puncture common Other barbed insect other outdoor 1991-1995 1991-1995 < 40- 5-12.5 pediatric older 11-64 * * intravenous other known chronic least primary tetanus injection-drug last fewer unknown toxoid armed prior formaldehyde-treated aluminum equal adsorbed higher fluid available single-antigen pediatric acellular available combined more Pediatric similar much younger pediatric older adult pediatric single-antigen periodic available primary older younger greater minimal protective vaccine protective complete clinical immunized last last rare last most minimal protective routine small minimal protective adequate protective other clean minor more last fewer acellular usual primary first second third fourth third less valid pediatric younger old first primary older first third second primary fourth fourth fourth fourth Routine Primary Primary 15-18 first ~12 primary last Primary 6-12 * first local systemic common systemic ~ most optimal last Additional protective first least last dose next frequent local adverse older primary prior diphtheria-containing more unvaccinated older prior primary first least third dose second prefer- first single unvaccinated older more recommended subsequent small active Adverse adverse common self-limited palpable adsorbed several other systemic common local diphtheria- tetanus- extensive painful shoulder frequent severe high further severe local prior Severe systemic such generalized neurologic few peripheral neuropathy Guillain-Barré toxoid recent available brachial rare additional severe allergic acute vaccine prior generalized ful f prior toxoid • severe severe routine minor tetanus toxoid-containing passive other clean pediatric American Red American other preventive RR-10 acellular young RR-7 Provisional available //www.cdc.gov/nip/recs/provisional_recs/default.htm vaccine- preventable Bacterial “ WHO-recommended neonatal lift.Tº lar 1998-W 1998.3-5 apprº ſ 11:35-5 whooping acute infectious first 16th 20th common major more widespread more major estimated small aerobic gram-negative fastidious special multiple antigenic active filamentous adenylate tracheal responsible clinical immune more subsequent clinical Recent permanent toxin-mediated pulmonary recent present alveolar Clinical clinical * contagious gram-negative active filamentous – adenylate ciliated epithelial respiratory * allow impaired Local respiratory 4-21 similar upper 7-10 cough il lness first insidious runny low-grade 1-2 occasional similar common severe i Paroxysmal second paroxysmal cough 1-6 paroxysmal | numerous rapid due thick tracheo- i bronchial long characteristic high-pitched cyanotic young appear ill distressed normal Paroxysmal first same paroxysmal younger gradual less paroxysmal subsequent many minimal Older infected milder asymptomatic present • asymptomatic mild classic classic persistent i.e. more more reported uncommon • more recent older other susceptible unimmunized underimmunized Older first multiple high Encephalopathy highest common most pertussis-related secondary m bacterial younger Neurologic such Neurologic common Other serious otitis severe subdural rectal encephalopathy pertussis-related younger younger such urinary rib characteristic physical laboratory useful young atypical preferred positive fastidious difficult direct successful catarrhal posterior selective antibiotic effective erythromycin trimethoprim-sulfamethoxazole first nasopharyngeal rapid sensitive specific available certain bacterial antimicrobial molecular _-__mi=L m 6-11 y 5-0 10-19 20-y nasopharyngeal useful screening nasopharyngeal low variable laboratory useful clinical serologic difficult serologic available clinical serologic national elevated white present classical absolute lympho- greater More laboratory available Medical medical supportive communi- antibiotic effective such trimethoprim-sulfamethoxazole close close younger four-dose primary minimal minimum first minimum dose dose minimum dose Close second fifth human insect important most respiratory airborne respiratory infected silent infrequent little Temporal distinct seasonal communicable secondary susceptible infectious catarrhal first cough Secular common 6-year more reported annual fewer ~1 catarrhal Secondary 1940-2004 i largest clear • highest average annual younger i younger recent older annual older older reported reported demographic detailed informa- many useful epidemiologic highest greatest severe recent available current clinical acute least inspiratory posttussive other apparent clinical laboratory laboratory-confirmed compatible laboratory confirmed clinical appropriate endemic sporadic outbreak acute least other Vaccine-Preventable available more probable confirmed formalin-inactivated clinical controlled subsequent observational primary whole-cell effective serious little last Local such whole-cell other mild systemic common severe systemic such hypotonic whole-cell lasting such develop- more purified acellular lower adverse Whole-Cell mid-1940s • • 5-10 Local adverse common Acellular full * * Clinical 59-90 Acellular purified inactivated Several acellular different different concen- Acellular available Pediatric acellular fourth fifth primary pediatric acellular available sanofi equal fimbriae available 2-phenoxyethanol single-dose pertussis-containing available reduced pediatric similar reduced pediatric aluminum sanofi same reduced aluminum single-dose several effective acellular effective whole-cell local systemic adverse serious adverse such high persistent hypotonic acellular whole-cell serologic various pediatric pediatric single similar “ new similar clinical similar available primary first 4- 8-week fourth third adequate other indicated fourth certain fourth earlier fourth least least third unlikely additional fourth Routine whºs whºs Primary 15-18 15-18 15-18 17-20 • same possible “ affect different necessary single • single primary fourth necessary fourth primary fourth school-age younger fifth whole same possible limited “ affect available available earlier acellular eligible recommended primary single different Provisional single single 5-year local systemic adverse less adverse less increased such close younger young Provisional single single recent tetanus toxoid-containing least shorter last tetanus toxoid-containing necessary close infant younger healthcare single more recent tetanus toxoid-containing shorter least close immediate pregnant single same other permanent single primary least such diphtheria-containing first least available adult older available single single close infant younger healthcare single pregnant single primary separate other e.g. single acceptable reduced primary fourth more primary age- valid primary final single-antigen least prior more last prior least prior Hib-containing prior first protective least high separate minimum first first fourth fifth younger fourth fifth other pertussis- necessary same possible total positive Other underlying neurologic possible potential neurologic more prolonged increased certain neurologic e.g. uncontrolled infantile progressive neurologic other neurologic stable neurologic idiopathic cerebral developmental other pertussis-containing necessary total positive unknown neurologic neurologic additional —typical clinical culture-proven Low-grade severe adverse common common whole-cell full multiple smaller altered inadequate significant likely full smaller divided less standard additional Satisfactory typical clinical culture-confirmed such other other other certain Adverse injected local such Local first Local frequent fourth systemic such low-grade whole-cell mild first less common higher whole-cell self-limited symptomatic severe systemic such higher febrile persistent last- longer hypotonic hyporesponsive whole-cell common fewer comprehensive adverse adverse full limited Available substantial local fourth fifth first fourth fourth increased other systemic supplemental state- entire upper certain acellular most substantial local self-limited fifth entire fourth extensive fourth fifth fourth fifth increased fourth fifth preferred improved whole-cell common adverse local such low-grade nonspecific systemic such gastrointestinal Local nonspecific same acellular serious adverse Adverse adverse entire dose Low-grade same acellular allergic prior identifiable * severe acute • higher other identifiable shock-like hypotonic • inconsolable > * allergic prior identifiable pertussis-containing previous tetanus toxoid-containing neurological • severe local prior toxoid-containing severe severe allergic vaccine prior due identifiable severe vaccina- mild such otitis upper moderate severe acute infrequent adverse subsequent adverse higher due identifiable shock-like hypotonic inconsolable longer communitywide precautionary adverse prior more additional severe allergic vaccine prior encephalopathy due identifiable pertussis-containing previous tetanus toxoid-containing progressive neurologic such uncontrolled progressive severe local prior toxoid- receive least last Td-containing severe moderate severe acute certain such higher persistent subsequent adverse extensive stable neurologic such controlled cerebral frozen freezing American Red American chronic acellular young antimicrobial Provisional Available //www.cdc.gov/nip/recs/provisional_recs/default.htm i | anti-vaccine untold Lancet booster acellular Extensive = spinal spinal classic compatible lower recognizable first early 19th next developed severe average older primary more paralytic effective last wild-virus global eradica- next transient gastrointestinal stable acid small ether-insensitive poliovirus minimal significant other ultraviolet primary multipli- gastrointestinal present less several local blood- central nervous anterior typical paralytic near ultraviolet • local central nervous • variable clinical inapparent asymptomatic Asymptomatic Minor non-CNS paralytic * able nonspecific clinical central nervous clinical abortive complete less poliovirus upper sore gastrointestinal abdominal influenza-like indistinguishable other viral Nonparalytic aseptic several prodrome similar minor abnormal last complete Fewer flaccid Paralytic prodromal further normal biphasic initial minor 1- 7-day more major superficial deep severe diminished deep asymmetrical sensory Many paralytic most present permanent m Spinal common paralytic asymmetric most cranial spinal paralytic Laboratory cere- brospinal diagnostic acute flaccid genomic “ wild polio vaccine early high fourfold Cerebrospinal increased white wild polio endemic only known inapparent asymptomatic immune deficient fecal-oral important oral-oral º seasonal tropical infectious susceptible greater susceptible • infectious Oral-oral possible present * onset stool 3-6 Secular 18th Initial least early maternal high continual paralytic rare lameness immediate frequent primary natural infrequent susceptible paralytic early inactivated oral paralytic last paralytic endemic wild several confirmed i paralytic i last imported recent direct vaccine vaccine-associated paralytic live oral 1980-2004 last unvaccinated several asymptomatic vaccine-derived unvaccinated least genetic early monovalent oral other first available poliovirus inactivated monkey 2-phenoxyethanol • single-dose prefilled subcutaneous intramuscular monkey formaldehyde monkey effective • certainty effective dose Oral live attenuated monkey single trace intestinal lymphoid vaccinated Maximum viral first first fecal vaccinated effective paralytic more protective least immune paralytic less local wild many complete Oral effective single more other live-virus oral lifelong excellent intestinal prevent wild lower low fourth fourth similar other exclusive wild-type less more paralytic sequential occur- vaccine-associated paralytic sequential vaccine humoral inactivated third fourth sequential Fewer complete complete complete paralytic polio available Exclusive live indigenous primary primary other first early second third = 1996-1999 sequential paralytic available whºs 6-18 4-6 fourth early available 4-6 complete maximum first necessary polio-endemic first second necessary primary immune third high preferred second third minimum minimum fourth fourth fourth fourth third fourth adminis- least fourth specific polio fourth necessary available routine polio complete minimum 5-component pediatric minimum first first same younger fourth fourth fifth older necessary most immune small increased endemic epidemic eastern laboratory healthcare close wild specific current wild poliovirus above previous available unvaccinated prior primary recommended standard third possible 1-2 6-12 second i separate more available least available least less available single recommended B- primary more complete further supplementary supplemental complete necessary additional subsequent polio endemic B- less full primary increased last necessary local serious adverse docu- local trace strepto- serious allergic • paralytic rare adverse live oral i live [ neurotropic i available paralytic | * 5-10 exclusive paralytic ſhe identical wild Most healthy permanent likely older likely immuno- normal immunocompetent higher certain B-lymphocyte available paralytic older paralytic * wild-virus healthy average healthy average vaccine immunologic abnormal equal first other m overall Forty- paralytic normal overall first first other able nonimmune prolonged revertant similar nonimmune last allergic prior further trace allergic anaphy- lactic such skin severe successful upper local prior current antimicrobial con- valescent acute same individual clear particulate allergic vaccine prior severe Last • polio free Last preliminary clinical epidemiologic suspected paralytic appro- local appropriate viral single paralytic immediate vaccine-associated outbreak wild unvaccinated epidemic older uncertain widespread many industrialized paralytic more fewer last documented indigenous wild suspected acute flaccid supplemental such national house-to-house last wild-virus—associated indigenous additional intensive international free indigenous wild detailed national global substantial last international other bilateral multilateral Rotary more Current global available paralytic new new postpolio postpolio syndrome permanent residual female postpolio oversized paralytic infectious more postpolio Post-Polio 14-534-0475 www.post-polio.org wild global updated Apparent global wild last indigenous wild virus-associated new paralytic -E- * bacterial severe first late 19th clinical microbiology secondary bacterial encapsulated unencapsulated capsular cerebrospinal capsular effective bacterial other invasive bacterial younger invasive younger younger influenzae gram-negative aerobic facultative vitro accessory “ nicotinamide dinu- • different a-f gram-negative invasive polyribosyl-ribitol responsible distinct capsular invasive ſ nasopharynx distant * upper tract contributing several “ normal common Nontypeable unencapsulated frequent human invasive exact unknown Antecedent mycoplasma upper contributing likely striking age-dependent common Passive maternal first presumed capsular protective precise invasive ug/mL unconju- purified long-term invasive anticapsular serum age-specific most asymptomatic small common antigenic so-called anticapsular Natural other genetic important genetic unknown single genetic immune Clinical Invasive many organ common invasive common clinical invasive pre- mental stiff other other neurologic appropriate antimicrobial life-threatening airway Septic joint mild focal severe common invasive common invasive acute due nontypeable otitis Nontypeable unencapsulated invasive virulent encapsulated Nontypeable rare serious common ear infected small gram-negative invasive pleural joint middle appropriate positive neurologic • effective antimicrobial important younger type only vaccine influenzae antimicrobial viable available rapid sensitive specific capsular negative false-positive similar aggluti- sensitive longer difficult Medical invasive Medical Antimicrobial effective chloram- • effective • Ampicillin-resistant Ampicillin-resistant common life-threatening etiologic initial empiric out- • asymptomatic only i primary respiratory firm m bimodal seasonal second contagious invasive consid- certain particu- close e.g. institutional direct secondary Secular influenzae reportable Serotype-specific incomplete national several active influenzae nationwide early younger popu- invasive late more invasive younger invasive Three-hundred due car- vaccinated unvaccinated age-dependent invasive peak older less invasive younger confirmed invasive younger young 1990-2004 o 0-1 12-13 24-25 36-37 48-49 confirmed Most recent unvaccinated vaccinated socioeconomic parental —school-aged -chronic three-dose primary Fifty-six older eligible primary age-eligible fewer unknown Thirty-two confirmed more more younger invasive due unknown actual Most unvaccinated vaccinated large house- low socioeconomic low parental school-aged African socioeconomic chronic higher Protective younger maternal Secondary less invasive secondary 600-fold higher general popu- younger older secondary first first second third fourth secondary trans- child Secondary high Most low secondary effective younger older negative greater available similar other polysaccharide pneumococcal meningococcal typical T-independent age-dependent poor younger repeated low-affinity minimal polysac- ineffective effective T-independent T-dependent young allow class-specific useful first immunogenic younger available young utilize different available 1985-1988 effective older variable ºf immune immunogenic old * less functional young • young utilize different available toxoid immunogenic More protective primary Clinical Invasive vaccinated uncommon immunogenic increased invasive such sickle-cell human infec- increased invasive primary conjugate separate primary primary three-dose primary primary ACIP-Recommended 12-15 primary interval primary • immunologic primary minimum least previous second third simulta- other immunologic subsequent dose subsequent younger interchangeable more protective necessary primary licensed primary older full current Detailed interchangeable primary dose primary more influenzae entire dose child current 15-59 least 2-6 months. ” 7-1 dose dose 2-6 months. ” PRP-OMP 7-1 dose dose least previous dose least last least last least unvaccinated single least last child single lapsed more up-to-date three- four-dose lapsed catch-up invasive protective anti-PRP younger invasive susceptible possible convalescent general older older immune asymptomatic older invasive functional anatomic e.g. sickle hematopoietic unvaccinated older high-risk least pediatric available sanofi whole-cell available app ºnstitute e.g add * ºs dºes protective invasive high-risk conjugate * separate other e.g. single acceptable reduced primary fourth more primary valid primary final single-antigen older least prior more last prior least prior Hib-containing prior standard pediatric immune younger 0-1-6-month primary fourth receive prior same individual • Serious adverse rare • Serious adverse rare positive chronic same adequate off-label positive unknown same individual particular third older least second common Systemic such infrequent Serious adverse rare Available adverse local systemic similar following concurrent individual due serious adverse severe allergic anaphylaxis prior moderate severe Minor mild upper younger immunologic same individual insulated liquid reportable most healthcare invasive local American influenzae Red American influenzae invasive near vaccine-preventable older influenzae invasive vaccine- preventable acute viral infectious early 7th Persian 10th dreaded smallpox. lifelong human monkey first live available universal more immune common fatal single-stranded important responsible viral responsible antigenic important acidic short less systemic primary respiratory regional primary subsequent reticuloendothelial further viral regional distal second initial other nasopharynx rash • contagious viral 7th universal fatal important light regional Primary viremia 2-3 5-7 clinical 10-12 • charac- higher * high runny mucous pathognomonic punctate blue-white bright red buccal maculopapular upper next downward maculopapular discrete confluent upper fingertip most involved same confluent * 5-6 Other anorexia diarrhea more more common younger older viral i common rash 1985-1992 stiff residual neurologic many other higher young common acute rare degenerative central nervous due persistent insidious progres- sive myoclonic rare early higher premature spontaneous low-birthweight definable malfor- Atypical inac- wild-type estimated Subsequent pleural maculopapular petechial urticarial purpuric vesicular Atypical live local severe wild immune young residual maternal prolonged mild discrete short Similar hemorrhagic high mucous clinical standard Positive serologic immunocompromised severe prolonged certain lym- typical several acute high younger severe malnourished bacterial high African Laboratory routine important molecular epidemiologic geographic viral urine nasopharyngeal virus suspected public Clinical viral same serologic likely virus serologic Clinical more rash detailed viral available enzyme-linked available diagnostic appropriate susceptible wild-type transient many Uninfected negative negative positive previous single diagnostic positive preferred other laboratory positive first false-negative negative first rash detectable least rash available indirect plaque Complement acute first rash possible second speci- same same specific titer confirmed second indigenous other human known asymptomatic large respiratory Airborne aerosolized closed late rash 1950-20 1989-1991 late communicable greater secondary susceptible rash first Secular epidemic actual More more highest 5–9-year-olds more more 2–3-year epidemic indigenous lowest annual school-aged younger younger first school-aged vaccine second dramatic school-aged largest younger first younger 5–19-year-olds Overall highest lowest non-Hispanic younger higher non-Hispanic measles-associated death-to-case Forty-nine younger fatal Sixty-four largest annual important low low many large preschool-aged early experi- preschool-aged few second black Hispanic likely white younger more high other many young due wild smaller higher wild-virus lower susceptible younger Large many other 1993-2004 low annual Many Most due preschool-aged 2-year-old fewer fewer low annual Available virologic other Most imported other aggressive low elim- achievable reported Relative increased older high many prior second school-aged school-aged uncommon preschool-aged prominent More several more largest pre- school-aged metropolitan More last large largest religious personal Most limited largest involved large measles-related pre- preschool-aged older low due recent high aggressive large suspect febrile generalized maculopapular probable gener- alized maculopapular longer higher noncontributory virologic confirmed confirmed probable laboratory confirmed clinical confirmed probable possible local international imported local indigenous indigenous more available //www.cdc.gov.nip/publications/surv-manual/default.htm • * first live vaccine live inactivated virus combined mumps-rubella inactivated fre- Two-dose unique atypical combined wild-type mumps-rubella-varicella Atypical original high live live strain fewer original only available live attenuated available * individual single-antigen chick lyophylized freeze-dried sterile preservative-free small human noncom- municable approxi- º. similar single-antigen first i incorrect primary Most vaccine th second passive other Most first second more first earlier first serologic vaccine-induced lower following natural serologic epi- demiologic vaccine-induced long-term most Most vaccinated anamnestic immune available secondary successful minor least least other adoles- first first measles-containing measles-containing first least second first second first catch-up second first least first earlier first additional adequate other acceptable documented recommended minimum valid * first primary 12-15 * first * medical first second possible less first valid Self-reported parental adequate adequate other acceptable permanent medical vaccina- specific 13th more indicated other older medical least least measles- rubella- mumps-containing other acceptable pregnant medical acceptable special other post-high educational medical international other post-high educational potential high-risk large sus- ceptible technical vocational other post-high other acceptable live other acceptable first second less prior other measles-containing first second least previous medical higher general Between least overall medical medical medical healthcare medical nonmedical full patient-care suscep- tible medical private public possible elderly low healthcare live least live second measles-containing least first acceptable medical medical first killed live last unknown attenuated unknown unvaccinated prior laboratory laboratory medical cost-effective appropriate tested susceptible timely necessary other acceptable timely serologic increased endemic epidemic many other certain unvaccinated least first killed live less last unknown unknown neces- sary permanent temporary immunocompromised maximum susceptible younger highest older live passive Adverse allergic subsequent susceptible adverse immune common adverse adverse susceptible higher lasting Most asymptomatic Measles- rubella-containing transient low apparent susceptible temporal clinical transient benign greater higher immune thrombocytopenic thrombocytopenic earlier other rubella-containing other mumps-containing other susceptible adverse more rare rare rare Most minor anaphylactic rare Allergic uncommon mild brief spectrum possible second independent nongovernmental American potential available current severe allergic prior e.g. i • anaphylactic serious measles- mumps- chick anaphylactic measles- mumps-containing other such • mumps serious allergic chick egg-allergic low skin-testing predictive allergic allergic i egg- • allergic prior routine i special • severe other pregnant pregnant Severe due congenital generalized large virus subsequent least immunocompromised susceptible close immunocompromised general large daily more more more least high-dose low-dose short-course less alternate-day topical aerosol intra-articular tendon high systemic alternate less component least component severe Available severe unusual adverse HIV-infected severe immunosup- variable asymptomatic HIV-infected symptomatic Asymptomatic other measles-containing theoretical viral other clinical such asymptomatic symptomatic severe immuno- Age-specific total severe HIV-infected other measles-containing HIV-infected severe severe HIV-related Total ul < < < total moderate severe acute manage- ill potential adverse such Minor e.g. otitis mild upper concurrent antibiotic other recent upper multiple previous subsequent antibody-containing immune whole red intravenous immune serocon- such concen- immune intravenous immune more thrombocytopenic significant direct vaccine-induced – natural greater potential justified greater subsequent prudent previous previous such other measles-containing tuberculin same admin- measles-containing same measles-containing measles-containing least theoretical measles-containing least favored less less average less recon- stituted same • first—give skin American Red American wild-type global fatal Jinfect congenital health-care 54:1229-31 global Viral Measles-mumps-rubella autistic second measles-mumps-rubella m − º- acute viral * 5th * viral infected filterable 5th frequent military • outbreaks military common aseptic sensorineural more common i military i ºute ſt same cross- single-stranded • antigenic various ultraviolet cerebrospinal urine infected ultraviolet i respiratory Mumps regional • • regional such inf ti 12-25 tiSSueS characteristic aseptic • ngſ Clinical nonspecific low-grade • 14-18 common low-grade infected unilateral º * single multiple salivary first many mumps asymptomatic additional nonspecific nervous aseptic common clinical inflammatory cerebrospinal post- Symptomatic stiff sequelae higher more -l. absent many º such rare less mumps testicular common postpubertal many postpubertal bilateral affected abrupt testicular last testicular rare ovarian postpubertal impaired infrequent transient reversible single virus many temporal few virus unilateral vestibular sudden permanent compatible symptomatic rare Complete Other less common arthralgia clinical particular clinical clinical acceptable virus nasopharyngeal buccal buccal upper best viral buccal viral simplest virus enzyme used available sensitive other serologic available detectable first few transient mumps-containing possible symptom acute-phase human asympto- matic nonclassical airborne direct infected Temporal late virus —positive —significant • * late active similar less infectious 4th active saliva Secular reportable 1968-2004 i ºwn relative highest older routine correlat- 1980-2004 i comprehensive º Several vaccinated high single prevent o mumps 1980-2003 more many likely many laboratory confir- due complete appropriate many suspected resulting mumps true 5-14 vaccine early 5–9-year younger late older older -40 m more urban suburban serologic clinical acute unilateral bilateral self-limited other salivary more other apparent inactivated short-lasting live available single-antigen measles-mumps-rubella individual single-antigen chick lyophilized freeze-dried sterile preservative-free small human noncom- municable More single measurable similar single Clinical vaccine-induced greater lifelong most vaccine least mumps-containing first mumps-containing unilateral bilateral self-limited other salivary > other apparent documented first Mumps-containing mumps-containing first least second first first second Few immune mumps second available most mumps first second second primary immune first dose long- i second first available combined second first adolescent catch-up second first medical least least measles- rubella- mumps-containing other acceptable high second second combined valid Self-reported parental adequate adequate other acceptable permanent medical specific 13th more indicated other older immune physician-diagnosed least live first serologic acceptable “ equivocal serologic susceptible Live peak 5- Most likely immune recognizable arbitrary nonimmune necessary immune immune effective harmful Adverse safe Most adverse such joint attributable compo- adverse large-scale • l * physician- adequate rare rare allergic prior severe mumps chick fibroblast allergic few Rare calculated vaccine evi- inadequate aseptic sensorineural mild severe allergic prior e.g. anaphylactic increased serious measles- mumps- chick most anaphylactic measles- mumps-containing other such serious allergic such egg-allergic low skin-testing predictive allergic egg-allergic prior routine special Pregnant theoretic fetal generalized immune immunosuppressive low-dose less alternate-day topical steroid immunosuppressive additional immunosuppressed human moderate severe acute Minor e.g. otitis mild upper concurrent antibiotic other antibody-containing immune whole red intravenous immune serocon- mumps least antibody-containing less refrig- less average less American Red American congenital relative Viral vaccinated vaccine- preventable “ little “ third separate German medical common “ German viral viral nasal acute widespread Australian congenital maternal early first congenital related such eastern western enveloped single antigenic other unstable lipid ultraviolet low respiratory regional Transplacental Fetal mitotic Clinical mild subclinical first rare older low-grade lymphadenopathy upper maculopapular 14-17 little red 18th variant distinct clinical German ultraviolet low regional 5-7 12-23 low-grade 14-17 second pruritic fainter prominent hot last several posterior cervical suboccipital many integral Other soft diagnostic common º i rare i same last rare chronic rare secondary low vascular thrombocytopenic common cerebral intrarenal last most Additional rare late progressive i 1964-1965 i main surgical/spontaneous • neonatal estimated retarded emotional disastrous early congenital fetal spontaneous premature many first fetal rare 20th overall third greater uncomplicated Congenital organ common sole congenital espe- fourth includ- Cardiac such ventricular pulmonic possible mental other progressive subacute older low high Impaired cell-mediated many subclinical only reliable acute positive viral rubella-specific significant acute- convalescent-phase Congenital fetal gestational first • spleen clinical serologic standard nasal urine cerebrospinal diagnostic viral intensive many routine Viral valuable epidemio- logic suspected viral common significant acute- convalescent-phase possible False-positive positive infectious positive serologic available laboratory available preferred Enzyme-linked sensitive available easy Most diagnostic “ most sensitive simple fourfold greater paired diagnostic recent rubella-specific primary rapid sensitive Commercial available false-positive due rheumatoid i human known extended true more • late airborne trans- respiratory infected insect subclinical asymptomatic Temporal temperate highest late early contagious contagious more large susceptible Secular congenital notifiable largest annual fewer less moderate due low annual independent available careful longer 1966-2004 predominant younger older less more 1980-2004 1980-2003 Most mid- Hispanic young largest annual due susceptible young Most reported foreign-born CRS Hispanic most Latin American Caribbean • unvaccinated most Clinical clinical following generalized maculopapular o maculopapular higher • lymphadenopathy recent suspected generalized acute probable clinical virologic laboratory-confirmed confirmed laboratory clinical laboratory-confirmed Clinical clinical following congenital congenital peripheral pulmonary pigmentary developmental infection-only laboratory clinical suspected compatible clinical probable probable laboratory other confirmed consistent laboratory probable eye-related congenital single compatible duck dog HPV-77 higher joint human other live rubella-infected aborted human diploid fibrob- • communicable available single-antigen ” rubella measles-mumps-rubella • nonpregnant individual born i single-antigen lyophylized freeze-dried sterile preservative-free small human safe immunogenic clinical more older serologic single More vaccinated clinical least Follow-up vaccine long-term lifelong similar single-antigen Several viremic vaccinated low detectable unknown uncommon clinical fetal vaccine-induced Rare serologic pregnant least least first first rubella-containing rubella-containing first least second immu- first first second Few immune mumps second available most mumps first second second primary immune first long-term second first available combined second first adolescent catch-up first earlier first second first older least medical least least measles- rubella- mumps-containing other acceptable high second second combined susceptible rubella-containing first acceptable pregnant pregnant Particular healthcare valid Self-reported parental adequate adequate other acceptable permanent medical specific 13th more indicated other older immune least other live rubella-containing first “ equivocal serologic rubella-susceptible rubella-containing acceptable routine presumptive immune unvaccinated congenital congenital acceptable pregnant positive serologic appropriate pregnant immune Medical unvaccinated laboratory laboratory important healthcare pregnant hospital detectable Clinical unreliable immune many many unrecognized only reliable previous reliable documented negative Such serologic medical cost-effective appropriate tested susceptible timely timely prior necessary other acceptable immune effective harmful Adverse safe Most adverse such attributable common lymphadenopathy adverse susceptible more common • • rare rare susceptable arthritis-like Population-based allergic prior severe such joint joint transient susceptible susceptible rare susceptible postpubertal acute acute arthritis-like transient peripheral neuritic such acute acute other chronic seronegative seronegative unimmunized neuropathy adult severe allergic prior e.g. pregnant pregnant fetal next generalized immune immunosuppressive low-dose less alternate-day topical steroid m immunosuppressive asymptomatic symptomatic moderate severe acute Minor e.g. otitis mild upper con- current antibiotic other antibody-containing immune whole red intravenous immune serocon- least adminis- antibody-containing rubella combined necessary more Previous human immune contraindi- anti-Rho immune serologi- vaccine occa- vaccinated mild serious pregnant pregnant pregnant likely pregnant next pregnant pregnant other theoretical pregnant pregnant likely next • theoretical vaccinate 1971-1989 • live observed routine rubella pregnant pregnant pregnant wild-virus such subclinical fetal susceptible susceptible observed vaccine-induced maximum theoretical low routine Individual small theoretical vaccinated pregnant less refrig- colder average colder recon- stituted low rubella several • high •Intensive • Susceptible indigenous susceptible young routine premarital possible at-risk special supplemental susceptible e.g. immune important adequate susceptible American Red American congenital health-care suspected pregnant congenital pregnancy—United rubella-containing persistent juvenile High congenital vaccine- preventable acute infectious herpes Primary 19th infectious vesicular acute Clinical vesicular Subsequent live attenuated healthy other first latent sensory Primary recurrent short infected regional primary other such sensory Further secondary viral mononuclear infected Clinical immunocompromised varicella viral premedieval 19th Primary Recurrent Short regional sensory 14-16 10-21 1-2 most 2-4 pruritic – ~18 mild first pruritic vesicular first highest centripetal mucous superficial delicate contain clear erythematous purulent Successive several present several macular same Healthy successive clinical healthy mild more severe higher gastroin- absent severe progressive high extensive vesicular high human severe prolonged primary lifetime healthy second common immunocompromised other viral natural wild clinical detectable Recurrent latent recurrent recurrent intrauterine young younger immunocompromised skin central nervous pulmonary hepatic vesicular extramedullary cranial sensory Most fifth cranial few systemic Postherpetic adequate available Postherpetic last Ocular other organ severe mild self-limited common secondary bacterial skin central nervous Secondary bacterial skin common outpatient medical Secondary invasive serious viral bacterial Secondary bacterial common younger nervous aseptic cerebellar common good infrequent cerebral common unusual acute unknown dramatic past Rare aseptic thrombocy- hemorrhagic clinical healthy rare • Most normal infrequent healthy older younger reported < 1-14 15-19 20-29 high serious high disseminated organ fulminant frequent immunocompromised pneumo- maternal overwhelming high severe fetal passive maternal maternal more prior benign due passive maternal Congenital first maternal newborn low muscular cortical micro- i skin congenital first neurologic small < congenital primary maternal first low less low less Rare congenital maternal virologic maternal Intrauterine weeks' ear- exact unknown m useful necessary routine combined atypical adverse wild-type immunized such laboratory frequent vesicular wild-type vaccine Rapid Rapid severe unusual specific antiviral rapid clinical Real-time available sensitive specific available available several real-time unavailable direct sensitive meticulous fresh fluid-filled skin excellent Other such nasopharyngeal bronchial cerebrospinal desirable skin positive such likely viral viral positive viral negative Additional //www.cdc.gov/nip/publications/surv-manual/ reliable valid distinctive subclinical unusual serologic necessary serologic useful serologic available Available complement clinical available standard early 1-2 4-5 longer immunocompromised indirect fluorescent indirect hemag- immune latex enzyme-linked sensitive specific simple available available sensitive simple rapid sensitive commercial false-positive latter useful lower Commercial sensitive vaccine-induced potential false-negative routine acute serologic significant standard commercial available false-positive common high reli- able 404-639-0066 404-639-3667 occur common tropical more distri- rural human insect common infected tract secre- respiratory airborne direct vesicular skin acute Temporal distinct seasonal highest early highest lowest tropical seasonal first contagious entire new crusted contagious contagious more Secondary susceptible high susceptible infected Secular endemic adult- approxi- notifiable younger highest age-specific earlier older active varicella-related 1990-1994 1-4 5-9 to-14 15-19 20- active * most 5-9 reduced 10-14 15-19 * notifiable Ninety-five first least live attenuated viral * early vesicular healthy varicella • general • < sequential embryonic human further human reconstituted small residual fetal combined live attenuated identical equal higher single-antigen logio plaque-forming = single-antigen detectable More least Japanese moderate severe effective more effective severe healthy second least second first clinical antigenic clinical Clinical healthy single similar separate long-lasting permanent vaccinated fewer fewer many maculopapular Most most recent younger younger several impotent inaccurate live viral varicella less 2.5-fold increased long-lasting most milder unvaccinated consistent breakthrough higher varicella less varicella more varicella more less 12-18 i prior necessary reliable 13th 13th reliable chick- susceptible severe frequent simultaneous first second first second i.e. licensed such equivalent first eligible vaccina- safe effective healthy same separate separate same least separate separate other other m reliable typical immune such clinical immune single least healthy detectable single older more first second first desirable higher routine specific highest likely older close high severe healthcare immunocompromised high other routine healthcare reliable healthcare serologic uncertain likely cost-effective necessary seropositive second available commercial sensitive 4-8 dose extended susceptible • cost-effective necessary i full correlat available vaccinated clinical i systemic infectious instruc other skin sick immedia va. º vac susceptible lo i susceptible healthcare potential vaccine-associated e.g. conta high serious such immunosuppressed * age-appropriate age-appropriate typical —non-U.S. born —all 1966-1997 parental laboratory non-U.S.-born atypical healthcare epidemiologic typical outb previc acute such valid other mild atypical m laboratory effective subsequent varicella prodromal vaccine-associated adverse post- potential healthcare recommended preferred healthcare outbreak exposed second outbreak second appropriate first least older Adverse common adverse such clinical local second local mild self- limited varicella-like effective effective > maculopapular vesicular common second present maculopapular generalized varicella-like i second º Most most maculopapular i live * latent similar wild Most less vaccinated wild less following wild-type mild such postherpetic mild li similar other live severe allergic vaccine Severe allergic prior prior dose minute * severe due generalized immune º vaccinated immunosuppressive • isolated humoral asymptomatic HIV-infected cellular isolated humoral e.g. i immunosuppressive low-dose less Immunocompromised alternate-day topical steroid moderate severe cellular human acquired asymptomatic symptomatic age-specific higher 3-month impaired cellular greater live varicella-like pregnant pregnant adverse manufacturer's insert American prenatal post- prenatal first second other healthcare varicella maternal—fetal pregnant 800-986-8999 moderate severe acute ill potential adverse such such otitis upper concurrent antibiotic other active common vaccinee rash antibody-containing immune whole red intravenous immune unknown potential antibody- same antibody-containing additional such least antibody-containing seronegative adverse i rare suspected secondary few secondary clinical Several suspected secondary wild several asymptomatic vaccinated close high such immunocompromised fragile extreme lyophilized frozen average frost-free low acceptable unsealed uninsulated small dormitory-style combi- capable required preservative other antiviral varicella unreconstituted short potent separate mishandled 800-9WARIVAX 800-982-7482 short possible central off-site difficult off-site high-quality dry appropriate colder average colder 800-9WARIVAX 3-4°F -20°C average human high • qiven available • 800-843-7477 -immunocompromised onset ºne clinical postnatal -susceptible pregnant susceptible immunocompromised • negative likely impor- greater general expensive maximum temporary high significant continuous playmate more i same 2- 4-bed direct immune neoplastic immunosuppressive postnatal less less gram adequate maternal immune immune pregnant increased such congenital postexpo- sure pregnant Higher immunosuppressed intramuscularly possible longer More detailed available //www.cdc.gov/nip/publications/acip-list.htm 625-unit last early severe high severe preferred available intravenous “ best anti-varicella clinical effective- available neonatal less weeks' less neonatal maternal pregnant pregnant illness maximum possible effective late adminis- tered recommended comparable recommended antiviral | routine healthy • chronic cutaneous pulmonary long-term steroid immunocompromised viral-mediated significant first last patient last rash hospitalized strict entire longer antiviral active Clinical beneficial new cutaneous systemic antiviral specific initial antiviral American routine antiviral healthy Oral healthy secondary severe Antiviral chronic cutaneous pulmonary long-term short intermittent aerosolized intravenous possible Antiviral routine pregnant uncomplicated oral pregnant second third American Red American Simultaneous other combined provisional updated Available varicella- related healthy vaccinated first Viral first | first epidemic military infectious long serologic definitive other non-B primary hygienic passive immune long-term widespread appropriate susceptible nonenveloped only natural several nonhuman stable stable low moderate high higher fecal-oral present biliary present several less clinical Most infected third longer • * • natural low high > chlorine • 10-12 15-50 specific symptomatic * asymptomatic symptomatic clinical acute indistinguishable other acute viral abrupt abdominal dark Clinical last longer symptomatic younger asymptomatic older symptomatic more fulminant case-fatality reported higher older older substantial associated medical ill Average direct indirect pediatric annual total more Laboratory other viral clinical epidemiologic acute detectable anti-HAV early convalescent anti-HAV detectable Anti-HAV convalescent present total anti-HAV anti-HAV anti-HAV total anti-HAV positive anti-HAV past Molecular such viral helpful investi- gate molecular Medical specific supportive endemic only natural animal chronic fecal-oral person-to-person present illness rare present Waterborne infrequent sewage-contaminated treated Temporal appreciable seasonal likely highest minimal personal sexual house- infected recent international Injection-drug Forty-five international illegal hepatitis A-infected only occupational chronic increased fulminant increased solvent/detergent-treated noteworthy critical common-source foodborne nosocomial rare neonatal intensive adult fecal developmental high fewer sporadic common Multiple common work-related serologic available important asymptomatic unrecognized other close large nationwide last high reportable distinct largest low annual symptomatic low marked highest early similar total anti-HAV general 6–11-year-olds older Anti-HAV highest Anti-HAV higher western other western Many high- routine late similar Many communitywide such high-rate intermediate-rate High-rate last several substantial high few older well-defined 1966-2004 = 1990-2004 1990-2004 Native certain religious high-rate high first-dose school-age routine young subsequent clinical other viral clinical epidemiologic serologic necessary clinical acute discrete serum positive anti-HAV inactivated whole-virus whole available • human i hydroxide i 2-phenoxyathanol available pediatric adult older younger immunogenic More protective seropositive single seropositive more seropositive * > seropositive first clinical seropositive protective m effective clinical clinical high clinical high long-term immune current available kinetic protective present longer Other cellular long-term unknown postmar- international other vaccinated little successful high routine older average annual higher least routine average annual more less successful high routine subsequent 12-23 • routine subsequent available single pediatric dose older deltoid needle Recommended 6-12 6-12 * initial subsequent initial available pediatric adult pediatric dose older dose first deltoid needle Recommended 6-18 6-12 * initial subsequent initial dose dose 6-18 first dose dose dose 6-18 first different manufac- interchangeable same preferable available acceptable first first pediatric pediatric minimum first booster calendar first booster necessary first immuno- adverse same other Similar equivalent pediatric equivalent three-dose long-term first third least first second least second third least necessary longer recommended older equivalent standard same single-antigen least second single-antigen pediatric intermediate- dose < * illegal • occupational chronic recommended recommended recommended local older high intermediate first second dose necessary long-term Available vaccinated first available complete high- less initial immune different anatomic younger younger high-risk Other vaccine other illegal occupational occupational hepatitis A-infected other increased due occupational chronic liver fulminant infected Susceptible liver Susceptible liver solid sewer increased routine local lifelong serologic past adverse such higher negative likeli- initiating low cost-effective extensive geographic high older certain certain high older available total high vaccine low anti-HAV routine diagnostic Adverse adverse local mild self-limited systemic low-grade fewer serious adverse severe allergic vaccine prior vac- preservative 2-phenoxyethanol older • common serious adverse allergic vaccine prior severe moderate severe acute inactivated theoretical low special immunocompromised uuith gamma concentrated human negative human Severe adverse rare more effective administra- clinical large gluteal single less possible more close sexual certain common-source HAV-infected transmis- high least injected live least least measles- mumps- rubella-containing live sooner American Red American Provisional Available active passive health-care green Viral Viral -º several similar distinct infectious separate early specific serologic acute 5th first smallpox human early middle 20th contaminated further first complete serologic natural effective small double-shelled Other duck small circular double-stranded numerous antigenic only nonhuman resilient infectious environ- mental least common chronic more infected chronic hepatocellular second known human More die chronic 5th human yellow • Numerous antigenic • least infected chronic hepatocellular Clinical • 60-150 average specific least asymptomatic Several well-defined hepatitis-associated antigenic subviral 22-nm spherical tubular variable infectious complete infectious present complete present nucleocapsid detectable conventional liver chronic soluble high high anti-HBs acute anti-HBs potential anti-HBc undefined recent anti-HBe detectable low Clinical clinical acute indistinguishable other acute viral average Clinical asymptomatic asymptomatic prodromal initial nonspecific insidious right quadrant abdominal dark icteric variable gray hepatic common other acute complete anti-HBs future most acute complete fulminant infected fulminant case-fatality acute severe most serious due chronic acute chronic chronic many infected infected chronic chronic asymptomatic aware capable Chronic responsible most HBV-related chronic liver hepatocellular chronic active more estimated B-related chronic higher hepatocellular estimated Laboratory clinical epidemiologic clinical definitive serologic Serologic acute chronic used acute early most early 1-6 mo sensitive infectious acute chronic acute undefined only serologic acute anti-HBc acute illness recent detectable best serologic acute negative positive single chronic Negative Susceptible Negative Negative Negative due Positive > Negative due natural Positive Positive Positive Positive IgM Negative Positive IgM Negative Negative Positive Negative 1-2 dose acute immune sensitive low susceptible false positive undetectable = useful infective higher protective anti-HBs acute immune recommended positive appropriate milli-international protective Medical specific acute supportive effective chronic successful chronic other infective other standard other insect parenteral mucosal HBs.Ag-positive chronic highest serous lower other such other unlikely 1-2 * positive infected infected positive infected infected global childhood common • global global —most important transmis- sexual heterosexual homosexual infected Fecal-oral asymptomatic percutaneous injection-drug important other percutaneous ear other sharp medical small overt needle such fresh cutaneous other infective other direct mucous such hand-to-mouth hand-to-eye infective infective mucous inanimate environmental various infective other Perinatal efficient positive infected perinatal positive many infected infected different global high chronic more HBs.Ag-positive moderate HBSAg-positive low less HBs.Ag-positive most most greater most early chronic greatest most asymptomatic little acute chronic liver high low chronic less low chronic infectious present present acute Secular reportable many reportable distinct serologic different available mid- first early injection-drug acute greatest acute new additional infected routine more acute approxi- perinatal Perinatal disproportionate chronic 1978-2004 Other common sexual heterosexual Injection- infected early widespread healthcare uncommon coC uncommon general less prevalent certain lifestyle highest infected frequent chronic high-risk injection-drug infected more user Homosexual o d high 10-20 35-80 É illicit parenteral 60-80 active 35-80 3-10 20-80 3-6 30-60 1-8 10-80 frequent 1-2 15-30 É retarded multiple 5-20 3-10 first-time 3-5 available less apparent attrib- uted several high large targeted major infected multiple injection-drug targeted immuniza- effective public private high-risk rapid high-risk low initial low comprehensive prenatal pregnant perinatal routine high plasma-derived 22-nm human safe effective unsubstantiated live other human first licensed recombinant second similar perinatal • high-risk plasma-derived recombinant infant adolescent * recommended pediatric pediatric common recombinant more yeast-derived final detectable recombinant infectious viral complete viral available pediatric adult different interchangeable two-dose pediatric younger Engerix-B aluminum preservative residual single- dose aluminum other single intramuscular more healthy more adequate age-specific three-dose protective * anti-HBs higher less * male immune effective clinical complete normal increased protective high necessary other immunocompromised recommended 40-mcg special Recommended ug ug ug ug 1-10 11-15 11-19 other immunocompromised 2-dose i 3-dose Higher more immunogenic specific 4-dose deltoid recommended anterolateral lower least inch least inch other anterolateral deltoid valid serologic adequate vaccine-induced immune • more • significant clinical anamnestic anti-HBs significant anamnestic anti-HBs significant vaccine normal immune routine i serologic immune longer additional i available annual hospital i younger pediatric Primary Primary 1-2 Primary 6-18 i intramuscular usual i positive ” “ unknown third highest last least m preferable 2-month other good appropriate difficult vacci- third least second first least third earlier necessary longer HBs.Ag-positive unknown Preterm low less chronologic preterm initial gestational likely full-term low negative first chronologic chronologic stable full available same pediatric equivalent individual separate other younger potential immune more positive unknown second least first least positive chronologic negative < positive unknown first 5-component protective least high minimum first first fourth fifth younger fourth fifth other pertussis- necessary same other pertussis-containing necessary possible total f total positive i positive unknown [ 11-19 age-appropriate routine adolescent immunization local deter- ideal young highest flexible older possible e.g. Asian active transmitted pediatric approved usual less third dose second accelerated minimum first minimum second third first third less less minimum alternative alternative 10-mcg anti-HBs similar standard 5-mcg alternative 2-dose increased older pediatric usual less third dose second accelerated minimum first minimum second third first third less less minimum necessary extended Primary Primary * third first least Alternative Heterosexual multiple long-term correctional pediatric increased sexual other multiple transmitted Injection-drug high injection-drug suscep- tible possible long-term increased injection-drug homo- sexual other high-risk undergoing increased large effective susceptible healthcare percutaneous permucosal public blood-contaminated such highest other allied equivalent pediatric equivalent three-dose long-term first third least first second least second third least necessary longer recommended older equivalent standard same single-antigen Other special behavioral medical disabled high-risk skin other infected present certain such endemic such important endemic susceptible susceptible younger high interfamilial unaccompanied high intermediate positive sex susceptible anti-HBs positive immune positive infected high more close local shorter sexual local common medical Other disabled unaccompanied sex high certain high intermediate common high certain such high specific casual low such special such medical severe routine younger potential prior routine expected immune high cost-effective high —Alaska —Pacific higher such -.g endemic injection-drug endemic-disease HBSAg-positive cost-effective low serologic such routine recommended subsequent most such i suboptimal such —sex HBSAg-positive —immunodeficient healthcare necessary HBs.Ag-positive final third fourth present anti-HBs present comprehensive recommen- healthcare healthcare sharp catch-up serologic necessary significant prophylaxis Routine low such public healthcare direct Several Older older male chronic Further primary deltoid adequate additional additional first second three-dose second usual 6-month 1,4-month accelerated healthcare second Fewer appropriate deltoid detectable anti-HBs anti-HBs negative low routine “ persistent detectable positive three-dose negative susceptible second usual • 1-2 second anti-HBs.Ag valid nonresponder probable parenteral HBs.Ag-positive difficult negative anti-HBs serologic possible negative true initial anti-HBs detectable likely vaccinated detectable true second anti-HBs sixth second expensive single anti-HBs positive likely previous further serologic anti-HBs negative “ second more seronegative total same cold ethanol high anti-HBs anti-HBs least passive accidental percutaneous mucous sexual HBSAg-positive perinatal younger old primary acute Most high-risk cold ethanol pooled low low valid current unavailable high chronic effective pre- acute chronic effective perinatal first same different available first second third first third other Subsequent routine pediatric HBs.Ag-positive less initial 3-dose next chronologic third second fourth unknown first positive possible important second Preterm less unknown maternal first different Complete • 9-18 > immune reliable preterm less additional Few available chronic i.e. HBSAg-positive off-label positive unknown younger same other older percutaneous needle permucosal exposed anti-HBs exposed unknown available n nonresponder positive unknown anti- adequate necessary anti- adequate necessary inadequate vaccine 1-2 inadequate vaccine immune immune adequate anti-HBs inadequate serum anti-HBs second 3-dose second Susceptible susceptible acute single last sexual last sexual more late chronic anti-HBs chronic primary increased chronic close unvaccinated primary first second second and/or nonsexual infected Adverse common adverse Adverse systemic such i Serious systemic adverse allergic Severe systemic rare febrile neurologic newborn multiple slight large population-based severe allergic vaccine prior further Such allergic allergic vaccine rare prior * severe moderate severe acute minor such upper Specific pregnant more inadvertent pregnant vaccine pregnant severe chronic newborn pregnant eligible live such suboptimal frozen American Red American multiple comprehensive m health-care occupational multiple Viral Viral neonatal Clinical \ = u infectious viral i 15th epidemic first epidemic least influenza infectious viral least 19th 1918-1919 20th “ Spanish influenza embryonated inactivated protective inacti- first live influenza influenza single-stranded orthomyxovirus Basic nuclear influenza • Single-stranded • • virus moderate other wild i Most natural milder stable less antigenic consequent immunologic yp human most subclinical epidemic influenza > neuraminidase i due sequential immune immune Antigenic interpandemic due serial influenza irregular • antigenic i major antigenic more 'ale lati larger ent protective new pandemic Antigenic due genetic new antigenic worldwide • antigenic last major antigenic prior wide geographic pathogenic avian antigenic infected Efficient person-to- necessary pandemic Antigenic Antigenic major minor Antigenic same past similar incomplete —may epidemic • antigenic most predominant drifted ” widespread last drifted different much late past antigenic i major pandemic single high greater individual large severe fatal large Secondary tertiary epidemic influenza lower excess major high excess respiratory high late early Sporadic isolated respiratory epithelial Viral docu- Clinical influenza illness prior immunologic anti- related general infected classic clinical “ abrupt nonproductive abrupt exact back tracheal epithelial runny substernal ocular last more such respiratory subsequent • • respiratory 5-10 1-4 illness prior related nonproductive influenza rapid several frequent pneumonia most secondary bacterial e.g. bacterial viral influenza viral uncommon high • • severe due Other chronic other chronic pulmonary older influenza influenza excess cardiopulmonary other chronic recent • influenza-associated older more influenza- older influenza higher higher • young certain young medical more • > influenza-related excess more younger greater predominant high high severe healthy high underlying medical younger comparable older American routine annual influenza influenza least less pandemic critical public local public federal available //www.hhs.gov/pandemicflu/planſ characteristic clinical nasopharyngeal amniotic allantoic chick certain viral demon- additional helpful local individual influenza significant influenza acute-phase less convalescent Complement serologic key human specific least fourfold diagnostic influenza clinic antiviral timely mos 496-1038 1-2 5-14 15-44 yrs 56-110 23-25 45-64 yrs 392-635 13-23 yrs 399-518 125-228 several * epidemiological * influenza clinical serologic laboratory airborne temperate earlier available //www.cdc.gov/flulprofessionals/labdiagnosis.htm only known chronic large virus-laden more infected large upper susceptible direct indirect respiratory such influenza Temporal earlier peak most peak tropical symptom symptoms more documented high-risk 1976-2005 high-risk medical two- major more total primary underlying expected due epidemic influenza standard previous 5-year influenza epidemic due consecutive available influenza available intramuscular inactivated —trivalent available final residual available pediatric 0.25-mL 0.5-mL available reduced preservative free sanofi available multidose thimerosal-free pediatric single-dose thimerosal-free single-dose only younger available multidose reduced- “ free single-dose older available “ free single-dose older influenza lºcate same • live attenuated temperature-sensitive cold-adapted replicate final residual single-dose other nasopha- vaccinated least transmitted attenuated cold-adapted temperature-sensitive i practical inactivated • effective healthy influenza less vaccine-induced antigenic • effective elderly prior • effective prior immunologic effective |- effective healthy younger similar effective frail older effective clinical elderly effective elderly effective effective unvaccinated likely healthy healthy randomized double-blind placebo- healthy culture-confirmed influenza culture-confirmed Other febrile otitis concomitant antibiotic decreased randomized double-blind placebo-controlled healthy several documented influenza outbreak laboratory virus greater temperate late early effective more routine influenza 1982-1983 effective old febrile antibiotic fewer severe * fewer febrile upper • fewer due upper fewer healthcare due illness • fewer antibiotic available influenza healthcare • other available patient high-risk accessible best undertaken high-risk healthcare younger first other influenza most influenza high-risk 6-35 IM influenza previous older influenza first least influenza Other such intradermal subcutaneous topical older older chronic Other • 6-23 i long-term pregnant • long-term chronic chronic aspirin influenza • chronic older chronic chronic following • chronic pulmonary such inactivated —pulmonary e.g. asthma e.g. cardiovascular such congestive * metabolic —renal renal such —any respiratory • human e.g. cognitive spinal other neuromuscular respiratory limited pregnant serious medical immunologic recent influenza-related more second third nonpregnant pregnant comparable nonpregnant high-risk medical influenza pregnant pregnant Available influenza increased Many protective inactivated influenza low protective second nºne inactivated influenza demon- transient viral vaccinated other such pneumococcal other similar influenza clinical serious influenza protective many higher nonpregnant comparable nonpregnant high-risk pregnant influenza many • many HIV-infected high-risk receive long-term high-risk younger • long-term likely elderly healthcare annual influenza include other outpatient high-risk high-risk healthy high-risk younger • essential immunosuppressed protective • severe * essential hool institutional routine influenza foreign e.g. increased previous high-risk influenza current available his/her influenza influenza receive eligible healthy 6-23 • healthy other influenza-related other younger annual high optimum eligible available late own influenza * medical influenza first previous 6-10 previous influenza vaccine l vaccine influenza healthy most close high-risk inactivated Close high wild-type high-risk high eligible i.e. healthy close immunosuppressed protected other concurrent other specific simultaneous immune such Other live same same least possible Simultaneous Other Other live same same Adverse Local common adverse Adverse Local Local transient common Local Allergic rare lºcal rare fewer previous viral last Recent systemic common immediate allergic such allergic systemic likely residual current influenza small immediate allergic i acute appropriate influenza documented occupational other allergic influenza similar influenza medical influenza potential vaccine con- most admin- intradermal indicate local delayed-type m subsequent other increased precise small difficult rare such annual swine less true adverse subsequent lower less severe pre- older medical influenza general low greater influenza greater prudent previous subsequent most high severe influenza yearly influenza adverse clinical attributable influenza clinical More approved healthy significant upper such runny nasal other systemic unpublished reactive significant other systemic reactive 12-59 nasal armong serious adverse younger allergic prior severe acute chronic medical • long-term inactivated influenza anaphylactic other vaccine • severe inactivated reactive other chronic pulmonary healthy nasal vaccine -40 higher vaccine serious adverse small such rare adverse Few available high such immunosuppressed chronic cardiac additional available high inactivated severe allergic prior inactivated moderate severe influenza younger older chronic medical reactive other chronic cardiovascular metabolic such renal such long-term other wild-type influenza inactivated other live-virus immunosuppressive Pregnant pregnant inactivated residual severe other moderate severe acute clinical nasal nasopharyngeal deferral adminis- influenza antiviral influenza antiviral influenza antiviral influenza antiviral insulated coolant few influenza multidose visible present frost-free separate dormitory-style refrigerator-freezer frost-free separate 35°-46°F 2°-8°C systematic automatic high-risk • adverse * individual prefilled total first upright attached dose- second other influenza higher high-risk epidemic-related influenza-related older older previous lower black Hispanic non- white fewer high-risk influenza effective high-risk outpatient inactivated influenza other residential long-term acute high-risk e.g. hospital outpatient high-risk high-risk administer necessary older inactivated unvaccinated other influenza prior appropriate influenza per- high-risk Antiviral antiviral effective older new active influenza dry uncomplicated older symptomatic more oral uncomplicated older symptomatic more influenza older Antiviral adjunct influenza-related Additional influenza antiviral current influenza —effective oseltamivir influenza new • influenza-related economic detect rapid preventive general referral likely high susceptible hospital preferred inactivated high-risk medical antiviral high-risk protective Antiviral unimmunized Other elective uncomplicated new necessary vaccine influenza-related economic out- rapid preventive unvaccinated high-risk weekly sporadic regional less widespread more state's Weekly available special Infectious available //www.cdc.gov/ncidod/EID/index.htm American Red American live cold-adapted intranasal influenza Influenza-associated influenza Available //www.cdc.gov/nip/publications/acip-list.htm health-care Hospital-based pneumococcal Viral Safe influenza asthmatic interpandemic younger prospective healthy placebo-controlled double influenza healthcare respiratory syncytial associated º- * acute bacterial isolated i other pneumococcal confused other More pneumococcal bacterial human More effective pneumococcal many antibiotic late polyvalent pneumococcal first pneumococcal first conjugate pneumococcal lancet-shaped gram- positive facultative anaerobic * Gram-positive short * complex pathogenic important experimental * Type-specific | Capsular i protective primary antigenic type-specific Type-specific protective complement pneumococcal capsular related other additional Most serious few pneumococcal most common invasive serotype patient geographic most common chest • hypoxia adult community- hospital-acquired bacterial higher elderly More higher elderly young • elderly cerebrospinal younger older common healthy asymptomatic upper military many natural understood Clinical major clinical pneumococcal pulmonary Pneumococcal common clinical pneumococcal “ invasive pneumococcal short abrupt single uncommon Other common pleuritic cough rusty rapid poor rapid many pneumococcal adult community-acquired hospital-acquired common bacterial much higher elderly pneumococcal pleural endobronchial More pneumococcal Pneumococcal pneumococcal overall high elderly fulminant clinical bacterial estimated pneumococcal pneumococcal • clinical elderly neurologic similar other i common bacterial nuchal cranial pneumococcal high elderly common Pneumococcal known common invasive clinical pneumococcal younger ly i ive common clinical invasive invasive pneumococcal i bacterial l- younger invasive bacterial younger routine pneumococcal younger i highest pneumococcal * acute common acute middle ear more least Middle ear frequent pediatric more pneumococcal routine pneumococcal pneumococcal younger significant invasive known º invasive pneumococcal invasive pneumococcal younger functional anatomic particularl sickle human high anatomic cell invasive • higher African i same American p certain racial ethnic particular African certain American Indian invasive encapsulated invasive pneumococcal 2–3-fold younger definitive other sterile available capsular lancet-shaped suggestive pneumococcal stained difficult i normal nasopharyngeal suggested pneumococcal sputnum more white fewer epithelial 100-power gram-positive capsular capsular precipi- rapid clinical spinal pneumococcal positive large Several rapid pneumococcal polysac- other available sufficient invasive pneumococcal Medical other common invasive pneumococcal resistant broad-spectrum vancomycin antibiotic available ^ • human asymptomatic • early human insect • respiratory direct person-to-person respiratory upper pneumococcal responsible such upper pneumococcal such pneumococcal increased high Temporal common early prevalent pneumococcal unknown respiratory Secular pneumococcal population-based More more invasive pneumococcal More pneumococcal nonbacteremic noninvasive Invasive overall invasive pneumococcal other sterile highest invasive pneumococcal young younger < 5-17 18-34 50-64 invasive invasive pneumococcal lowest older Invasive 1998-2003 pneumococcal invasive young invasive pneumococcal younger prior invasive older less young older vaccinated other close preliminary Active pneumococcal sporadic pulmonary pneumococcal common crowded such correctional invasive high common crowded invasive high 14-valent purified pneumococcal capsular first polysaccharide pneumococcal purified capsular different pneumo- 23-valent 7-valent d §§§ coccal 23-valent Pneumococcal 14-valent polysaccharide pneumococcal bacteremic pneumococcal cross- several capsular additional bacteremic polysaccharide available available single-dose 5-dose Pneumococcal first pneumococcal purified capsular nontoxic acute otitis younger pneumococcal available single-dose More healthy Older chronic younger most poor least healthy more certain underlying various clinical Overall effective invasive effective pneumococcal significant underlying effective normal such high capsular bacteremic pneumococcal Cross-react additional pneumococcal effective invasive effective pneumococcal Pneumococcal immunogenic young high-risk medical effective invasive effective * —chronic functional severe pneumococcal pneumococcal significant vaccine-type non-vaccine-type more healthy immunogenic sickle large clinical invasive invasive more fewer underwent fewer unvaccinated nasopharyngeal pneumococcal older older normal chronic cardiovascular pulmonary cerebrospinal older increased pneumococcal splenic surgical multiple chronic renal nephrotic such organ high-dose corti- longer older asymptomatic symptomatic Pneumococcal special social pneumococcal such certain Native elective least feasible possible 2-week other immunosup- pressive possible complete verbal uncertain unknown pneumococcal influenza same different most single Pneumococcal younger high-risk medical primary fourth same other routine separate younger minimum older least older full current least least 24- high-risk medical 12-15 fewer 24-59 high high healthy single chronic least older Few available high invasive pneumococcal sickle other immunocompromising chronic immunologic least first sooner more high invasive pneumococcal additional high-risk sooner last Routine healthy Pneumococcal Pneumococcal * immunocompetent i invasive certain highest higher better serious pneumococcal > first dose available pneumococcal T-cell-independent sustained “ Available substantial revaccinated improved multiple pneumococcal routine immunocompetent 23-valent older highest serious pneumo- coccal likely rapid pneumococcal high-risk second more first previous highest severe pneumococcal less highest older functional anatomic e.g. multiple generalized chronic renal nephrotic —functional anatomic other e.g. —transplant marrow —chronic renal —nephrotic immunosuppressive long-term * older second pneumococcal more younger first Pneumococcal age-appropriate primary Adverse common adverse Adverse pneumococcal local -50 —conjugate less —conjugate Local first systemic such common fewer severe systemic adverse rare transient clinical immunologic Pneumococcal Fewer local severe e.g. limb Local common fourth first clinical pneumococcal higher primary whole-cell most febrile attributable acellular same higher severe adverse attributable pneumococcal severe allergic prior further Such allergic rare severe acute moderate severe acute minor such upper pregnant adverse high pneumococcal pneumococcal possible insulated coolant pneumococcal polysaccharide few Pneumococcal Pneumococcal multidose m least pneumococcal polysaccharide older population-based random-digit-dialed noninstitutionalized older older pneumococcal lower chronic high-risk Effective other long-term More severe pneumococcal few pneumococcal chronic likely high pneumococcal infrequent subsequent hospitalized high significant pneumococcal American Pneumococcal Red American heptavalent pneumococcal Active Available pneumococcal young pneumococcal vac- RR- Pneumococcal • • lower chronic severe pneumococcal 3-5 few vaccine influenza pneumococcal RR- influenza pneumococcal years—United pneumococcal invasive pneumococcal invasive pneumococcal protein- polysaccharide pneumococcal conjugate pneumococcal Meningococcal severe meningococcal 16th first definitive spinal bacterial focal such sub-Saharan meningococcal first quadrivalent Meningococcal major meningococcal quadrivalent aerobic gram-negative several nonpathogenic such cytoplasmic outer several other necessary complement-mediated capsular main serologic distinct asymptomatic nasopharyngeal groupable invasive relative geographic other such * sub-Saharan bacterial focal • gram-negative least invasive geographic other nasopharynx distant • contributing * 1992-1996 Most common pathologic hematogenous —petechial purpuric major sub-Saharan further certain outer Molecular specialized pulsed-field elec- useful epidemiologic colonized small less colonized blood- many bacteremic cerebrospinal purulent antecedent upper contributing Clinical meningococcal common invasive meningococcal hematogenous similar other acute sudden stiff other such mental Meningococcal bloodstream meningo- invasive meningococcal abrupt petechial purpuric acute adrenal multiorgan common meningococcal otitis less invasive meningococcal appropriate antibiotic many permanent such hearing neurologic meningococcal terminal common functional anatomic meningococcal genetic such mannose-binding risk Family infected meningococcal upper active passive African low socioeconomic higher low socioeconomic likely such nightclub higher invasive meningococcal least fatal patient meningococcal higher meningococcal other similar Laboratory meningococcal sterile bacterial low antibiotic cerebrospinal gram-negative meningococcal polysaccharide cerebrospinal rapid specific false-negative common unreliable Serologic e.g. enzyme meningococcal -terminal Exposure -concurrent upper tract socioeconomic -active passive Meningococcal 1998-1999 * old •18-23 old * 2001:286:688-93 empiric antibiotic appropriate • * late early clinical meningococcal similar other bacterial empiric broad-spectrum third- appropriate Many effective Few penicillin-resistant endemic epidemic only natural many asymptomatic transient most pathogenic groupable respiratory direct Temporal highest late early meningococcal secondary Most secondary secondary general meningococcal estimated due meningococcal younger highest early early older invasive twice overall low other young recent different last most meningococcal due serogroup Nongroupable less available due due meningococcal less sporadic localized Most additional meningococcal Large meningococcal endemic meningococcal several higher industrialized Meningococcal 1972-2004 1-4 5-14 15-24 25-39 40-64 Meningococcal 1991-2002 1996-2001 due • recent first meningococcal sanofi current sanofi subcutaneous bacterial capsular lactose * 10-dose preservative subcutaneous vac- available single-dose 10-dose Fifty-dose available single-dose sterile 10-dose sterile clear available Meningococcal Meningococcal sanofi e capsular • intramuscular toxoid dose isotonic meningococcal toxoid intramuscular single dose similar other polysac- pneumococcal effective younger typical independent age-dependent poor younger repeated low-affinity poor protective younger measurable substan- first single healthy antibod- detectable vaccine-induced likely school-aged least younger more less younger older Meningococcal serologic single similar single meningococcal similar least fourfold serum bacte- titer more longer asymptomatic respective Pure polysac- little older single same other different anatomic Routine recom- relative younger highest sporadic short older routine 2-10 available available same other indicated separate separate Meningococcal unvaccinated high Other meningococcal —all —other ſºon-kotnvasive routine increased meningococcal acceptable available * :1-21 meningococcal 11-55 meningococcal military el acceptable hyperendemic epidemic available terminal functional anatomic :1-21 sub-Saharan increased occur meningococcal —military annual geographic hyperendemic epidemi —terminal anatomic :1-21 same other separate separate meningococcal vaccine-preventable least probable primary meningococcal less primary more population-based age-specific a-3 serogroup meningococcal i applicable vaccine- other vaccine-preventable meningococcal more probable primary —period * Population-based e.g. age-specific younger Such i high * older • althou first acceptable acceptable asplenic endemic longer More available next present Adverse Meningococcal Adverse mild i local such i last i 1-2 such i Fewer systemic adverse similar frequent local Systemic such Meningococcal Less systemic severe severe adverse severe anaphylactic vaccine prior allergic further prior moderate severe routine minor vacci- adverse pregnant available • severe acute insulated freezing i Single-dose multidose meningococcal reportable most healthcare invasive meningococcal local Antimicrobial primary sporadic meningococcal antimicrobial chemopro- close infected Close household child oral mouth-to-mouth endotracheal tube m antimicrobial direct respiratory next prolonged more sporadic meningococcal greater total healthcare meningococcal higher general secondary close highest antimicrobial possible less more limited nasopharyngeal helpful preventive effective nasopharyngeal acceptable antimicrobial chemopro- antimicrobial meningococcal other other third- eradicate nasopharyngeal other chemoprophylactic nasopharyngeal Active provisional meningococcal Available Meningococcal Red American Meningococcal Bacterial meningococcal Invasive meningococcal young meningococcal Lancet Meningococcal conjugate meningococcal laboratory-acquired meningococcal meningococcal clinical * acute infectious human Chinese 4th 6th derivative first intentional susceptible scab 15th great cowpox first last intensified global last indigenous global Other large brick-shaped double stranded different most other other other monkeypox other aerosolized ultraviolet greater skin viable several longer low higher chemical such major severe Chinese 4th late 18th Last Last indigenous viable chemical regional oral pharyngeal major severe illness – * severe – virus Physiologic important vaccinia variola multiple different other many natural nature other such first western central pet susceptible regional asymptomatic further second first prodromal small oral pharyngeal characteristic Clinical clinical different distinguishable specific such major severe extensive higher greater major case-fatality more last major first late 19th severe case-fatality less = many last last indigenous principal clinical major relative immune clinical ordinary most mild flat Flat hemorrhagic severe uncommon fatal febrile usual vaccinated virus asymptomatic common preeruptive ill infectious Ordinary more smallpox unvacci- nated ordinary prodromal third fourth better red oral pharyngeal ulcerate large cutaneous visible highest first infectious skin few proximal distal Clinical unvaccinated uncommon uncommon 2-4 infectious mucous approx skin red oral/pharyngeal ulcerate saliva highest first skin 2-4 proximal second third raised third fourth vesicular 0-1 opaque skin 2-3 erythematous distended 6-12 central 13-20 pustular 21-28 flattened common other pustular sixth seventh skin Between maximum small second third seventh eighth high pustular single particular tral same • different centrifugal i ºne-ºn most more * same more Most centrifugal • general clinical pustular numerous confluent febrile toxic less severe less severe ordinary-type •Rarely fatal skin superficial more typical few numerous fatal major Flat flush ordinary-type cer- large flat-type soft flat severe little severe i Most fatal severe toxemic extensive skin seventh eighth flat ordinary-type little umbilicated soft Respiratory common flat-type most fatal Flat severe uncommon extensive mucous gastrointestinal large Indian hemorrhagic hospitalized pregnant mucous prodromal intense i fatal dusky little Hemorrhagic early late early hemorrhagic second third other mucous seventh few insignificant cutaneous present hemor- early eruptive flat vesicular severe illness late vaccinated sudden tempera- normal other laboratory significant variola such true subclinical major serologic subclinical bacterial uncommon • skin elevated • most eighth illness overall ordinary viral bacterial indistinguishable acute perivascular due fatal sixteenth clear involve multiple uncontrolled overall ordinary-type younger hemorrhagic greater less smallpox common blindness corneal due recurrent variola important other i most resembles varicella important other other rash severe febrile high least Most short mild little more severe likely other rash febrile likely more additional such abdominal ill normal confine important classic different deep round umbilicated superficial delicate uncommon single same more centrifugal several same new several more severe rash useful first maculopapular other febrile maculopapular such other vesicular Other common smallpox least limited vesicular adverse recent smallpox • febrile prodrome fever 1-4 rash Other • hard • • umbilicated • same * rare smallpox- such rickettsial small present hemorrhagic flat-type lethal primary |Most common varicella-zoster viral elderly dermatomal classic regional disseminated ill possible pattern external iris recurrent simplex mucous Enteroviral mild 1-2 rash maculopapular whitish- grey flat oval peripheral simplex major febrile other- immunosuppressed smallpox high moderate low major Major febrile prodrome 1-4 higher rash least following systemic least additional * deep abdominal deep same umbilicated * severe abdominal same m centrifugal greatest distal relative first oral toxic individual present high major Immediate sure respiratory local digital possible infectious such high smallpox moderate febrile other major more minor high moderate infectious possible febrile low febrile fewer minor differential available //www.bt.cdc.gov/agent/smallpox/ high clinical probable smallpox laboratory other other clinical distal oral Patient toxic moribund * classic same major minor minor diagnostic specific acid-based • clinical high pustular generic available other nucleic acid-based such Serologic acute direct moderate important rapid diagnostic infectious clinical disease predictive positive low close smallpox clinical false-positive serious common common false immediate rapid diagnostic important suspected rapid available clinical useful direct anti-VZV con- sensitive specific dependent careful vesicular rapid clinical Real consistent diagnostic available least private academic large local Other simplex diagnostic rapid available local positive alphaherpesvirus confirmatory available Medical public medical clinical clinical local contact smallpox critical Smallpox infectious major person-to-person airborne trans- fine airborne negative smallpox same other infectious such suspected appropriate protective higher disposable inadvertent other contaminated susceptible protective other Reusable hot such laundry smallpox appropriate protective contaminated Medical supportive antiviral Recent antiviral useful therapeutic serious renal off-label Antiviral other investigational new infec- tious public suspected Most transmission face-to-face infected hospital large airborne • most frequent first only natural chronic early global smallpox only known airborne oral nasal pharyngeal infected Most direct face-to-face infected physical contaminated viable dried skin uncommon fibrin infectious first prodromal infectious first trans- i.e. frequent first most skin intact present longer less frequent general severe infectious slight Secondary Natural slow close face-to-face most high prodromal severe prodromal medical = frequent unrecognized Secondary infected global smallpox next potential close further effective low Temporal similar highest tropical seasonal evident present Secular last early intensified global initial twofold ensured least sur- numerous national epidemic civil other difficult cultural apparent low key global • Last indigenous contain- enormous last last more particular intensive strict last deadly difficult few difficult intensive last indigenous additional more last fatal global vaccina variola clinical acute higher deep-seated same other apparent atypical such flat-type low high vesicular high maculopapular smallpox first nasal powdered smallpox successful lasting severe rural cowpox same safer smallpox 19th smallpox same distinct smallpox available live infectious Smallpox current early lyophylized freeze-dried 100-dose tetracy- small available effective safe full-strength additional immunogenic additional multiple special bifurcated vaccine s needle civilian neomycin cell smallpox available genus-specific cross-protective other * detectable primary primary – smallpox unknown primary percutaneous standard detectable more primary first higher higher second • controlled smallpox * vaccine high primary substantial waning more high longer greater primary smallpox remote vaccinated less severe i 1950-1971 fewer vaccinated > • disease less vaccinated vaccinated more unvac- < 11-20 125:161-9 secondary m lower unvac- cinated lowest secondary less less severe i.e. modified primary primary clear Jennerian pustular third permanent major successful protected major revaccinated skin similar primary faster primary typical other major equivocal several possible equivocal immune viral allergic compo- equivocal potent incorrect general equivocal possible More available smallpox available present vaccinia other such other important primary viral successful major immune viral allergic incorrect impotent unvaccinated < less severe modified-type vac 3-4 5-6 7-11 erythema 8-12 typical nonimmune Routine military rec- • routine • laboratory occupational other other healthcare smallpox intentional smallpox • non-highly routine i.e. f smallpox attenuated lab • military laboratory non-highly attenuated other infect other outbreak other * other healthcare such recombinant clinical recombinant recom- public other smallpox intentional i initial direct medical public smallpox laboratory process clinical smallpox infectious such responsible medical present other medical military public initial confirmed suspected case-patient infectious Other public smallpox successful major routine younger confirmed occupational attenuated recombinant other nonvariola least increased virulent empiric Adverse pustular successful take. old new unvaccinated average average average larger specific clinical bacterial mild severe Most mild moderate normal common smallpox recent unvaccinated higher higher common constitutional ninth common past more higher primary experienced higher virulent successful * —can Susceptible lymphadenopathy 3-10 Susceptible temperature • recreational present g Maximum viral crust inadvertent 25-529 i vaccinia 23-242 skin i.e. trans- 10-39 frequent smallpox i primary inadvertent primary common eyelid nose Most specific f. other significant * primary Most eyelid erythematous urticarial primary specific afebrile rare bullous • other skin other normal skin Most normal minor little minor little i residual limited residual minor i toxic serious i immunosuppressive primary severe vaccinia eczema progressive post- vaccinial rare least primary frequent older primary life-threatening adverse smallpox anticipated adverse serious cardiac adverse civilian smallpox ischemic localized systemic atopic skin skin active mild limited severe fatal serious vaccine primary Severe active skin primary severe progressive metastatic cellular humoral primary fatal antiviral more common human post-transplant aggressive antiviral primary postvaccinal primary younger primary central nervous such Most allergic direct viral nervous affected complica- develop permanent specific postvaccinial rare smallpox Fewer fetal primary early Fetal congenital past active quiescent severe fatal metastatic impaired immunologic cellular fatal older primary allergic neurologic sequelae fetal Most prima early smallpox rare allergic vaccine prior Physician-diagnosed primary postvaccinial progressive adverse smallpox available //www.bt.cdc.gov/agent/smallpox/ smallpox severe allergic prior lymph trace glycerin sulfa-type new significant immunosuppressed Significant many generalized solid cellular humoral autoimmune autoimmune significant immunosup- high-dose corticosteroid Many weight higher higher more immunosuppressive live other live high last physician-diagnosed cardiac such late adverse physician-diagnosed current first Live viral smallpox pregnant pregnant least close smallpox past other chronic exfoliative severe increased inad- vertent exfoliative chronic exfoliative skin younger young other occupational public younger moderate severe smallpox same current past exfoliative * severe persons—no Unexposed immune intravenous only i available solvent/detergent-treated ºccinated sterile purified human healthy ocular high anti-vaccinia plas- postvaccinial human progressive severe vaccinia such eczematous such aberrant accidental isolated other special postvaccinial due likely effective adverse antiviral animal unclear vac- investigational new careful second-line smallpox standard investigative i.º stable Reconstituted less vial m i.e. more early intentional smallpox detailed interim local suspected key smallpox early introduced case-patient detailed critical smallpox febrile better American smallpox local critical smallpox healthcare other critical certain military civilian high-threat certain overseas general Adverse smallpox —contact other critical certain high certain overseas general public Supplemental adverse smallpox preevent Available Clinical undiluted diluted smallpox vaccinia-naïve military biological medical public smallpox national smallpox ten statewide national Available //www.cdc.gov/ncidodſeidſvol.7no1/leduc.htm new Available //www.cdc.gov/ncidodſeidſvol.7noé/rosenthal.htm Smallpox temporary variola zoonotic spore-forming Greek black biblical fifth early Indian Greek 17th estimated human contagious first microbial first live animal improved animal live human cell-free improved cell-free large aerobic spore-forming gram-positive common such long square viable infective many potential direct infected skin infected sufficient paraformaldehyde phenol amino such least proteins—protective lethal edema lethal lethal responsible biblical animal anthracis aerobic • viable • * responsible broken mucous intracellular antiphagocytic edema • effective vegetative • * cutaneous gastrointestinal clinical —cutaneous most common natural rare clear adenylate extensive mammalian wound vegetative cationic lymph intracellular further lymphatic large overwhelming widespread organ tracheobronchial mediastinal extensive massive inhalational inhaled alveolar lymphatic effective vegetative effective nonvegetative spore therapeutic nongerminated numerous delayed cutaneous gastrointestinal Clinical clinical cutaneous gastrointestinal incubation human m Cutaneous more cutaneous occur anthracis-contaminated animal other reported cutaneous small pruritic necrotic characteristic black Secondary primary painless Other adjacent cuta- neous initial cutaneous antibiotic less antibiotic Gastrointestinal intestinal contaminated intestinal regional lower acute Initial abdominal bloody gastrointestinal unknown common intentional median first bioterrorism-related several Initial non- productive 1-12 necrotic black painless —with • 1-7 oropharyngeal cervical fever abdominal bloody diarrhea 1-7 radiographic mediastinal antibiotic antibiotic prominent first bioterrorism-related brief prodromal Rapid high pleural mediastinial due hemorrhagic case- intensive Initial influenza-like similar early nonspecific other Most other such runny common common common common Most chest x-ray most abnormal primary influenza secondary bacterial cutaneous characteristic shallow black * clinical skin vesicular typical gram-positive pleural ypical gram-p º difficult other severe gastrointestinal PA-based i typical helpful difficult chest useful clinical bacterial great advanced visible unspun peripheral Gram-positive present other clinical such pleural oropharyngeal cerebrospinal positive Other pleural PA-based specific capsular m important therapeutic i • sensitive several additional active oral –30-60 antibacterial such resistant other such bioterrorism-related received antimicrobial more active survival higher previous apparent survival antibiotic therapeutic previous intravenous e.g. least other active intravenous oral longer aggressive such pleural acid-base mechanical cutaneous first-line Intravenous multidrug cutaneous systemic extensive Cutaneous simultaneous high cutaneous appropriate cutaneous eschar current common agricul- tural inadequate cutaneous gastrointestinal rare human • * communicable rare cutaneous main resistant physical chemical many dormant certain common direct infected skin taminated cutaneous such important human infected undercooked airborne aerosolized industrial contaminated i larger i difficult able smaller small lower * rare Naturally-occurring rare rare • i infected other animal animal • Biological rare m other laboratory-associated and/or infected animal strict rare effective bioterror- first Temporal Animal-related contagious Human-to-human cutaneous rare Secular most anthrax-infected anthrax-contaminated animal true human difficult unreliable largest recent human annual human early Most cutaneous single cutaneous 20th recent domestic wild animal single other intentional bioterrorist Most infected 1951-2004 veterinary live veterinary cell-free human cell-free Cell-free toxigenic protective other cellular adjuvant small preservative direct compatible cutaneous respiratory gastrointestinal laboratory affected other laboratory least supportive suspect compatible alternative laboratory supportive compatible environmental corroborative anthracis local first live bacterial improved live unencapsulated principal veterinary occasional live unsuitable early 20th potential first human minimal short-term adverse only human late higher protective protein- free only FDA-licensed human cell-free fil- toxigenic nonencapsulated dead live cellular more aluminum principal responsible detectable first • more human fourfold anti-PA earlier precise cutaneous controlled clinical human mill alum-precipitated PA-based ºr i cutaneous * ~~~ * Overall x placebo controlled available younger older protective alum-precipitated earlier several animal different reflect human protective pulmonary unknown animal i Initial • * * neous investigated annual annual other licensed entire anthrax extra six-dose primary local injection-site reduced intramuscular subcutaneous Preliminary fewer longer similar high aerosol standard routine clinical * increased e.g. certain military animal animal Routine insufficient Routine recommended low animal other high certain military other select intentional first federal medical private available nonhuman post- protective effective current optimal human vaccine-induced more fourfold precise clear nonhuman sufficient Adverse common adverse local minor local less moderate local severe local more Local Subcutaneous several multiple systemic Systemic mild common rare Adverse several routine limited due local more injection-site Adverse chronic * effective • effective PA-based plus • current FDA-licensed various doxycycline postexposure doxycycline-alone minor severe • Severe animal significant adverse few short-term laboratory 25-year unusual unexplained life- adverse general convincing elevated long-term adverse epidemiologic Persian possible several Current scientific available younger older Adverse high Several specific local systemic adverse available randomized severe anaphylactic vaccine prior allergic prior Previous severe adverse * severe moderate severe adverse underlying low-grade pregnant licensed recommended Pregnant m potential potential side related adverse breastfed immunosuppressed necessary suboptimal procaine demon- vitro rare such effective germinated effective spore non- human delayed prolonged other exposed less similar nonhuman human prolonged former lethal initial aerosol Such inadvertent biological terrorist procaine procaine aerosol 30-60 more * third pregnant mg 10-15 mg/kg mg mg/kg antibiotic possible antibiotic antibiotic suscepti- Antibiotic antibiotic penicillin susceptible minimum inhibitory attainable oral potential aerosol antibiotic least available standard 3-dose effective subsequent additional cutaneous gastrointestinal Cutaneous rare gastrointestinal possible current expert clinical antibiotic ciprofloxacin 877-BIO-THRAX prolonged biological more least likely h ffensive biological offensive biological stable many high least unknown likely biological high greater other potential biological hospital- other bioterrorist Eleven inhalation postal direct several direct contaminat- ed Several antibiotic available intentional interim public bioterrorism-related interim antimicrobial cutaneous bioterrorism-related Clinical epidemiologic human systematic biological Bioterrorism-related inhalational first safe A-1 A-2 A-15 Antibody-Live A-19 Immunocompromised A-20 //www.cdc.gov/nip/recs/child-schedule.htm Spanish black white 4-page 2-page pocket-size accessible Downloadable commercial Interactive //www.cdc.gov/nip/recs/adult-schedule.htm black white 4-page 2-page pocket-size Downloadable commercial accessible last adolescent A-1 recommended routine dose recommended subsequent feasible special tº recommended Catch-up other respective detailed significant adverse available 800-822-7967 old hospital immune unknown possible possible HBs.Ag-negative rare original HBs.Ag-negative laborato- medical monovalent vac- second final permissible monovalent positive next well-child tetanus acellular fourth early third unlikely acellular adolescent 11–12-year single Subsequent primary final second least first second susceptible reliable ceptible least Meningococcal Meningococcal old unvaccinated high Other formeningococcal fresh- meningococcal acceptable invasive meningococcal terminal anatomic functional certain other high RR-7 older acceptable Pneumococcal heptavalent pneumococcal certain final Pneumococcal certain high-risk MMWR certain limited cardiac human respiratory respiratory healthcare other close high healthy close healthy influenza-related healthy attenuated acceptable intramuscular influenza vac- influenza first least least i.e. least new routine 1-year-old broader certain high American • American More Than give minimum ” first final first current necessary final final 12-14 current typ second ºlā further first further previous final current -12 necessary * current -24 final turnal final current º liffirst CATCH-UP current further healthy first further healthy previous Minimum first current first necessary fourth fourth current first third final all-IPV all-oral fourth least second necessary third current primary catch-up five- last further 3-dose second iſ 2-dose susceptible adverse federal additional 24-hour national toll-free 800-CDC-INFO 800-232-4636 vaccine-preventable local ſº v dose Meningococcal more recommended medical routine other detailed complete significant VAERS available 800-822-1961 available 800-338-2382 vaccine 1-dose broken populators- vaccine other medical occupational have other prior 202-351-6400 available CDC-INFO 232-4636 § 1-dose || 4-8 * | 1-2 6-12 * co-e | chronic end-stage renal pulmonary elective chronic terminal chronic > cerebrospinal long-term other present medical lack occupational other prior American Special close high severe healthcare immunocompromised high e.g. young institutional correctional military nonpregnant age-appropriate least parental typical non–U.S.-born atypical mild epidemiologic typical acute labora- tory pregnant pregnant pregnant Dose dose Medical chronic pulmonary chronic renal e.g. cognitive spinal other neuromuscular respiratory respiratory severe influenza secondary bacterial severe Occupational long-term Other other long-term high i.e. in-home high-risk uncertain complete primary tetanus toxoid-containing primary primary first least third dose second primary last wound American second single full pediatric tetanus- diphtheria-acellular available immune medical laboratory second outbreak killed unknown postsecondary educational other measles-containing HIV-infected severe adequate born laboratory rubella unreliable laboratory child- determine pregnant pregnant ravic “ healthy nonpregnant high-risk immunocompromised special influenza inactivated Pneumococcal Medical chronic pulmonary cardiovascular chronic liver chronic renal nephrotic functional anatomic e.g. sickle elective least immunosuppressive congenital immunode- close possible highest multiple generalized marrow high-dose long-term cochlear Other certain American Indian other long-term pneumococcal One-time chronic ſenal nephrotic functional oranatomic e.g. sickle immunosuppres- sive congenital multiple generalized marrow high-dose long-term one-time primary Medical chronic Behavioral illegal Occupational Other high intermediate Current 2-dose Medical special 0ccupational public-safety other allied Behavioral injection-drug more previous Other chronic correctional international high intermediate chronic Meningococcal Medical anatomic functional terminal Other first-year military meningococcal hyperendemic epidemic e.g. sub-Saharan dry local annual Meningococcal above meningococcal acceptable high e.g. epidemic weeks–11 available older chronic good American minimum dose º interval dose next next dose 1-4 1-4 2-17 6-18 DTaP-2 DTaP-3 6-12 DTaP-4 15-18 influenzae Hib-2 Hib-4 12-15 IPV-2 2-14 |PV-3 6-18 IPV-4 Pneumococcal PCV-2 PCV-3 PCV-4 12-15 MMR-1 ” 12-15 4-6 º 12-18 ºf 12-23 6-18 18-41 6-10 Meningococcal Meningococcal Pneumococcal tetanus acellular acellular available separate equivalent American American RR-5 minimum oldest individual minimum equal greatest individual + available less old other § least least least first older fewer older pneumococcal young RR-9 younger old footnote * younger older first congenital RR-8 older least younger old second more first * influenza younger first younger influenza older second meningococcal high meningococcal second acceptable RR-07 § Subsequent minimum preferred previous previous tetanus-containing * second highest serious pneumococcal likely rapid pneumococcal previous highest severe pneumococcal younger pneumococcal RR-8 Table Þ < ：-） ſ- E- uw ºnoroziunului ſo ºooo-lºº ºnubav oſou uostało uouuzunului uosui， nuwun， qow www uouov uofficznunului opow-wºw uelqo uſ jou- issoulli uonnebøua oubyen uomocou uoueoſ uoue uowae 11- pinous suºlowen uleuo：| suºsiođe suÁ9-t 1-9 uur ubupių， ºuroopa ºutunenuos-proxo snutnou uønje uiuuw ouuo.jpuÁs onnor | uolueoſ uogop uoſ qoud owussouſoud |a uiuiae uotsin uo z gol uiuuw |…itºloi uou uonnebau） uonesipurunuo， uomocou uo uomocou * uç uoleſ esop poſtupovaun ulo ne uut uouiſì ſe uoue uu9 uomið trae- -woud uonje uovº ſurſuſ ulouſ uoſ s ºinpouss （sop-， a-xuosuuſ unde tºº-ºº un au uola uo-t i xewqtuoso sop ože uou oinpoubs a-xuoºuza unumo i o ºs op-， aut suſjedoh uo ur '-0 o uoo ne uooaenoq uoo uonnºsau） sºuºsºsop-g- su uomocou uopeoſ upisau uoupliųo unuluw snowoud （pd-soordine ne lov suo： u u uno sooſi øyow suÁL isel oºr suÁzſ-11 uopliųo uorsooq sissnuod uy uomocou uoºuno， suÁ9 unupiųo ºppuuq uoue uovið | |- arid suÁL uoupliųo ruusu-şi sous uzi •| • suÁ9-t （uusi-si uuq uz uiuuw upju uourou ſe ºud-i osop uuoqwou u uourou uu9 uſųųw uuoqwou øanısod-ºvskih ubųnou u uu9 ao uç 1-zı ſo dn lo usºnup-oſuus słºw.rz unui uoluro uowae plnous uſ osop uus 1-9 osop uuz-ı za osop loud ušnouum o uoupių， uoupotpununuo， suopeoſ |- uøųno uoneuropew dn-ųomeo uou unumour uomº uæquo uoneuropea uonov uoneziunului seua uouuz unului uo pºdepv uoſ uo • wwI uun |-|- lol sissmuod su ºsłoow uſųųw jo uomocou oſnow|ſºudrup pinous uoºunoſ uoupių， o quidoosns- uzi usuplių， uſųniw ubauð ºsn uspio uuzl uoupių： ºđe uusi-zi i awuſo- īnī£5，55755ītī5põWT|- uonnexou osip uo uwoux uxo |- olloqehou ºupno- tuonpuos uopun un uopuosip oud-|ºsłºwę -ç sºuboea wuuu-usuu | o uomocºu Į ºarăuÁc ，|- pºrºnwºo ）|- suºs'uopio uso jo use-9 unupių， szlo owuo.0 |- ne ‘ suÁó-vuº soouſ sosop owo-¿ uugz-oplių， out- nuotraul uo su-ſe uo uonnaeyðu… ojco-siuojųo un uonounjsÁp upou （su oweų- jo uſz-9 out- uopeoſ unuo，oouw uoupių： ut uoezuanuui sºwº-rioj uºstº qad un suh- uo uºaſă diovºos |-|×- | ssop-ųāų uo ui uaajºuſinqola Į ouboeae wollow oarų pºz istol- ubauð owussouddnsounului uuou-ſºuoſ uspoſ ir uoqaeunaeJ|- ºwl5p| untriloqnu uo uºaſă usoop uzi uo un sduunuu ºubºrº su uo ouroopa uomocou onbelºu suÁ9-t owo-| niwlºw uomið pinous esop v-ººr uusi-zı iſ | |-|- uouocunuui uo uppuauuuuooºx nouou u uºaſă biza uo • uºlųºnundu'uwde uoqae uo uomiº joj ſpuolunųswº-tº plnous uºploſou ºuboeae pur noſ ºps-，| uonroſpunenuos neoeud £ sonssi uæquo •uropew dn-ųomeo uou uoquour uouº upo annou uøųno uopeupbea uoņezĮunuuuul uoſ catch-up other related mild 12-13m give Previous anaphylactic earlier unvaccinated compo- last boosterdose earlier previous |-Hib interchangeable different “ previous severe necessary primary “ 7-lim |- older least dose dose • |-Dose early younger anaphylactic henny least unvaccinated high-risk give older dose previous severe acute next High-risk sickle anatomic/functional previous pulmonary renal least iſ least previous least final high-risk anaphylactic older older dis- functional anatomic least previous severe acute least following previous anaphylactic older -Live elevated local older severe acute -Wish chronic MSM high |-l routine other ococcal older following younger older functional terminal meningococcal hyperendemic epidemic e.g. dry Other meningococcal Previous anaphylactic neurologic diphthe- severe acute younger ：-） |- 5-O- 5-O- nozae uuam） o mºenuo： uotsiatou untuð uoſ uuentiae uorsuo， nuounº saevi usia voºrºpy jou ºu ºsa， u teſoujo alov uou- ºu omnoc ojowos uonne！ jo uomocou uolueoſpuſe o osuus odcom uoaſă •sop uºplo truoj uon joj uoneuropea ou ouin-ºuo- uwouxun uoneuroopa æsop wun-suo uoaſă uod ununul ut suosiad ſcual uripul urouxiiv.05 uso uneluxo ui uusiſoqoole otuojųo ſo uossoulli aelod suosiad noe woux Áųnedo uonipuo： uºpuosip uouro uonbcou o omeu！pow uonnesºud uomocou snoward uolueoſ o uut lºquiaox1 usquios（x） ut umboo uoneuroopa uºquomo uomio uouov uouuziuntuur own uolneziunului uo uºpuoluuuooº u uuou c. auoſuv ſeuon ut uo nuouno ou o uopluſo auoq-jo-ino subviuos suosiad ubenuo， * su-le ouw uxuo low ourouſe：H-czubnuuſ uonbos un * su-le uoquoue uwae uou uolneuſų|× suonipuoo oqi otſw usò suÁór daud-uou rzuan uuſ ol sºunºs ut su uo tuouſ lo ououw oä uopſtilo ºurou-jo-ino ouro aelow uostºs ou uwiſow su-ne uniw suosuºd-pwt neįmosntuounou uolueildse ueb ſo » quae suosisa-l u leaſul|- suosiºn-ezuanuui| Þ < ：-） ſ- 5-O- ºuroopa uon ºssºurii ºmej：pow- uomocºu o uſºwen jºisooq ueb ºd -odxò ajouw pº sºuºs puc ºutpuedou ºuboeae ！ubova ºutui e utni w xuopuks sını snowolae |-ºutosex uon |- suurär ou， uolºq noe • suoſinebau， |（siux-moduloo uomocou unuo.O loi suonºpustintional ajou un ut own uogi sleuoluipºsu unaised ºslonpoid ørow uz 1-9 lle puuſºq lov |pomeuboeae un seu usisooq 10- nºmeu un depuu uoueumquo nou » ispio sob uoutubovaº ønow own sop uio usawae oºp oq ı loovae uou |-|- ºutpooluscouq ovos uou susuoduos outo oi snowoud uoueo » suomeoſpuſe c — — nixuuiwael io-1 noſ ucis ubow.lºq oveų ou usº col ſa ia usownaq uit joj Anisod-ºvskih isu-ų3ıH uo suÁç punow powia unoſ vuºqqdup umsooq uºlºq mpe upuxº un urchqo |- oq uoneuropea sonuotant souoſtroqet |-cu qru ut uoloeſ-ºſuuſolo uniw uoui acq oqae uotu uw w utdei ſpurteaz uºrsºw ouw ſe suaequixum naqa ubojos ul upijo suosiad aansod-ºvskih siue ſouos quae umcuxo sonuſuoti uuon-ſuoi |-p suoſiow umcuxo ut sisślepoulou uniw xºs uwu ut nºuurd utin usºnour uºstº i uoueursı ulupe uoſ suoņepuauuuuooo！ uoueussew uuouw uod º Þ |- （w sw：wp-t- laid uoană nou lala upis ulInpuºqni uoneopunenuo， ºssoulli un uoſitae o ºos ised ut uavnº unqolae 11- uonesipunwujuos uonepcu osop-iſºmų nunul uuni uomocou unulow inoq ou • ucun uouoos ni || ut uouſow uomið pinous | uoneuropew vuotuow upuſow low uuoq own pinous uºſtų uolųno eustutſdrp jo uomocou uoueo » ouroopa sonunuo， ne sı， uoneopunenuo， øro， un uoli -v uo uopuauuuuooºx oos u u^ bIZA 'custrid 11- „ dioviļnsuoo ºsop-iſºmų uo ºnow 9-XIX soloucuðilæuu uondºpenuoo uuni smijo uomoeau o c. ſep uo ·la sx.ws-ruowae ºviso ubus * su-ų （Kepuluiq uo uostº ellºqnu uontuottinoop istoſ plnous sºn uſoq u uloq ſurnuliw-.bs× ou ouw susidoſomųojonyw -ºpuſ， （ſºunt-ox1 uostos- ump ucieuſes-qns uſoq aeſ ſo -uatu upiųw u u lºwen ouw suosiða- luotuºſduloo ſtuttual o aðalſoo.| uneluopun suosiad isoo uoli upo uodoj jo uſ se uolue ut ut polow pue pinous sumpt uoquour ubanº uco ouroopa ſuņupe suoņepuauuuuooo！ immune different measles-containing mg monoclonal maximum negligible Whole 80-100 intravenous mg/kg maximum syncytial immune 300-400 thrombocytopenic correct immune entire additional immune immune immune observed immune gamma globulin ” syncytial asymptomatic symptomatic human severe other immunosuppressive 3-dose dose anti-HBs serologic dose serologic prior serologic prior primary 3-dose acellular healthcare Meningococcal on-the-job fecal 3-dose 0- 1- 6-month anti- dose •If least ml positive immune further •If less ml negative unpro- 3-dose anti-HBs dose —If positive immune further —If negative consid- susceptible known probable parenteral possible per- positive positive Anti-HBs vacci- nated original expo- anti-HBs negative protected. non-preg- nant healthy younger annual out- home-health patient close immunosuppressed transplant protective medical immune desirable • immune nosed “ equivocal nonimmune appropriate first live more least live least live acceptable rec- unvaccinated following laboratory laboratory immune reliable effective Routine commercial sensitive vaccine-induced 3-dose primary tetanus/diphtheria-containing necessary acellular Meningococcal unavailable accept- able recom- older give Table additional specific official state- www.cdc.gov/ nip/publications/ACIP-list.htm • A-19 humoral X-linked common variable live uncertain humoral immune varicella severe selective Other live safe Pneumococcal effective cell- humoral Complete severe complete live * ineffective Partial most Wiskott-Aldrich ataxia- immune early effective late effective granulomatous leukocyte Live bacterial secondary bacterial safe effective Live viral safe effective “ routine bacterial viral yellow Pneumococcal chronic granulomatous inactivated effective immunocompromised Malignant bacterial immune * effective renal effective Live bacterial viral yellow “ HIV-infected > * routine Human Oral Passive Red American [ 71-72 RR-4 [ 1-18 B-1 B-4 B-14 B-16 primary diphtheria 4-dose 3-dose Act-IB tetanus 4-dose adult Minimum adult adult Pediatric pediatric Minimum Minimum vial prefilled 6-35 prefilled Intra- viral nasal Japanese viral viral viral viral viral viral bacterial eningococcal diphtheria bacterial 11- bacterial bacterial diphtheria viral viral viral viral bacterial bacterial Biological bacterial bacterial toxoid bacterial bacterial viral viral taneous Yellow viral licensed inactive necessary finished pharmaceutical vac- anti- other immunologic suitable further pharma- ceutical reasonable manu- human protein bovine protein DTaP-Hep acids oral green residue Ethylenediamine-tetraacetic Preservative residue Yellow formalin preservative DTaP-Hep Japanese solvent nese oral Yellow DTaP-Hep most most most most oral residue Japanese cellular residue Meas- antibacterial red phenolsulfonphtha- Preservative DTaP- most most glycol p-isooctyl- viral inacti- nonyl viral inacti- DTaP- most most solvent Yellow Meas- multi-dose precise contain- con- tidose Japanese single-dose trace lower refrig- stable unspecified protein Proprietary protein poliovirus combi- fertilized Yellow YF-Vax Stainer-Scholte con- DTaP-Hep bovine extract DTaP-Hep green poliovirus Japanese most meningococcal fetal DTaP-Hep Synthetic/semi-synthetic yeast * Canadian thi- joint 48:563-565 Immunologic 1387-92,1397-1401 Clinical 1997:32:77-84,87 harmful preserva- 112:1394-1401 * unspecified 2-Phenoxyethanol 2- 2-Phenoxyethanol 2-Phenoxyethanol 2-Phenoxyethanol cº-Tocopheryl multidose p- multidose 2-Phenoxyethanol 10-dose unspecified Ethylenediamine-Tetraacetic 2- unspecified 2- oral refrigerator- stable Ethylenediamine-Tetraacetic equivalent thimerosal-free biological additional individual ’ lyophilized decreased equivalent thimerosal-free post- biological * pasteur single –– — pasteur Hib-Hepb adult/pediatric preservative free preservative free multi-dose preservative free 2005-6 MENOMUNE-A/C/Y/W-135 multi-dose single _M-M-R Wyeth-Ayerst equivalent tº tº .edu dose sanofi dose * [ dose dose dose dose f DTaP-Hib dose dose sanon t dose sax.56 −r-— dose º dose s28.63 dose dose pack-1 dose dose dose dose dose dose 11-15 º |Hip- pack-1 dose dose seasz2.53 sanofi spack-1 dose dose dose sao.37 dose sanofi B-14 Private dose dose dose sanofi Acellular dose dose dose dose dose dose preservative www.cdc.gov/nip/Vfc/cdc_vac price_list.htm Private dose sº.51 dose Adult- dose dose s36.91 dose dose dose B-Adults dose dose dose dose dose dose dose preservative sº dose sanofi dose sanofi dose dose dose dose dose dose preservative =-m Table table many international Table Vaccine-Related many foreign English many Table Vaccine-Related Russian Ukranian Latin difficult international unified Table Several Indo-European Table Western European Scandinavian available comprehensive complete == table many international complete acellular acellular whole whole whole Chemo-Sero-Therapeutic whole live military human immune human = 1987-1989 whole live live immune yeast Chemo-Sero-Therapeutic live military pediatric acellular acellular acellular polio = generic acellular generic live enhanced recombinant whole live attenuated Tick-borne = whole whole whole recombinant plasma-derived live 1969-1979 live 1970-1973 immune = live acellular whole whole whole enhanced inactivated whole Japanese = live live live live live whole Servier MFV-Ject whole live generic live live = live live live live live live live generic generic generic whole oral whole oral oral pneumococcal 7- = acellular acellular pneumococcal 23-valent 7-valent 7-valent live * m 1959-1968 syncytial immune generic LM-2 live LM-3 live live generic live live live generic oral live live oral = injectable live syncytial immune Pharmaceutical generic adult immune generic = oral acellular acellular acellular live acellular acellular live oral live live generic adult pediatric live oral parenteral injectable parenteral typhoid tetanus live live live injectable live oral = m oral live live immune generic live live North American * Vaccine-Related many most complete Serbian Spanish German Japanese Romanian Spanish pob Serbo-Croatian German German Serbian mºd German French | rengkong Spanish Japanese German Norwegian Spanish Spanish German convulsive Spanish Romanian Serbo-Croatian Serbian Vaccine-Related > |- Indo-European noocab Western European TEnglish- French TDutch German Italian Norwegian Spanish tº- |- – |- |- i C-1 C-12 C-13 C-14 C-15 C-16 insulated vial frozen Unused multidose Special earliest dated vial recommended vaccine-Pediatric —Pediatric vaccine-Pediatric insulated Single-Dose frozen Manufacturer-Filled Special earliest dated vial manufacturer-filled vigorous sanofi sanofi sanofi pasteur recommended m insulated Maintain frozen current vial Multidose Manufacturer-Filled hub Special earliest dated recommended frozen insulated dry Warm Warm white red further own exterior frozen freezeſ manual frost-free necessary most Careful necessary frost-free new 2005-2006 2004- current dose more impenetrable Special earliest dated live recommended ſ |-T insulated Maintain frozen vial [ insulated Maintain frozen vial ulgate 7-Valent homogenous white vigorous Special adjuvant vigorous earliest dated haride Single-Dose Multidose Unused multidose Special Intradermal severe local earliest dated recommended C-10 dry dry present frozen freezeſ separate Acceptable standard last standard separate sealed Dormitory-style appropriate necessary most Careful necessary Protect Special warmer other recommended 1-800-609-4618 earliest dated live recommended | sanofi pasteur.co.in 800-822-2463 baverhe 800-288-8371 drug-service 404-639-3670 800-200-4278 medical www.ask.com/products/vaccines.isp 617-983-6400 general 800-635-1766 lº 800-666-7248 dyour vaccre ºur maintancj dºscs rºcoivºd vacGre settle hold-style corrrrle-cla-style d-ºrruto tº separate o- uſes reſtige cric so-natthe longest shortest vaccine hose wil refrae-a-or sm extra cold other Ice-filled old ºne clinic whorn “ next erºr adequate expºsed urjamaged va-cne manufac- aſſe-led Ier teſt op-anec detailed local “ ſaffirgo sºmeºne cº-5 crg colder Order least monthly Expired com- earliest earliest outdated * large stable cold open Frequent vaccine electrical pro- tected electrical perishable immedi- ate auxiliary specific recommended other local ngdº-49 org fºr Expensive electrical Expensive electrical Expensive electrical C-15 vaccine • Interactive Order m-m ID-13 D-16 vaccine critical recommended clinical practical theoretical following general supervisory professional vaccine American state/agency-related competency-based vaccine and/or active vaccine nearby scheduled Many other available standardized Basic inaccurate misleading Health-care other reliable open safe trust-building informed multiple Health-care important health-care patient uncomfortable ºr subjective multiple individual previous important planned vapocoolant non-aspirin-containing age-appropriate Age-appropriate non-pharmacologic separate next • Health-care vaccine single effective good alcohol-based antiseptic vaccine soiled mandatory vaccine potential open important needle stick appropriate follow-up state/local syringe/needle accidental needle medical • critical =-mm separate parenteral prescribed engineered sharps available many needle stick potential clinical desired optimal immune needle prescribed viscous fine 22-25 • Needle-free new needle-free needle stick health-care improper more needle-free last lyophilized Diluent specific uncapped entire diluent lyophilized needle necessary possible equal needle contaminated vial needle mº- vial needle injected positive allow single entire vial multidose desired vial excess • allowable increased difficult Other vaccine possible bacterial filled other immediate vaccine more large few few clinic immediate live unstable identifiable appropriate labeled partitioned recommended imperative appropriate optimal severe local adverse adequate | deltoid adult- influenzae adequate mL 22-25g adequate deltoid 22-25s 1-2 mL- Influenza- live mL intran-ai upright trivalent adequate 22–25-1-2 deltoid e. young 23-25-5/8- Posterolateral upper s-ºrg Anterolateral young Meningococcal sc upper 23-25s adequate deltoid deltoid Pneumococcal Anterolateral young 23-25s 5/8- Posterolateral upper tº adequate 22-25-1-2 tºwn Anterolateral young upper 23-25s young upper 23-25s adult 2-dose tº adequate 22-25s 1-2- 1-2- complete particular Subcutaneous fatty above usual vaccine thigh upper necessary upper | 5/8-inch 23- 25-gauge needle appropriate circular fatty light several dry m several vaccine lateralis anterolateral deltoid upper Deep ~ femoral ~~ \_-Sciatic lateralis upper intramuscular middle femoral right intramuscular deltoid older deltoid adequate -Deltoid 22- 25-gauge needle needle adequate typical various 7/8- 1-inch older 7/8- 1/4-inch 1- -inch appropriate circular acceptable pediatric geriatric needle light several dry new entire multiple same more same 1-2 local recommended maximum same suggested deltoid same necessary acceptable different inadequate nonstandard specific Special familiar hemophilia other similar 23- firm least • vial natural severe anaphylactic allergic rare Medical local contact individual orthopedic necessary primary health-care individualized • vasovagal “ vaccine patient vasovagal allergic supportive life-threatening allergic initial suspected current detailed medical allergic rare 15-20 vaccine vaccine permanent medical common lower lower right state/local complete available clinical safe effective appropriate private scoring pediatric self-assessment annual perfor- corrective appropriate safe effective annual self-assessment pediatric medical probationary several s special comfortable thern ask applicable Medical medical clinical up-to-date vial new iden- probationary aseptic correct needle I-1/2 draws proper eg prepared disposable appropriate Intramuscular subcutaneous anatomic specific appropriate f steady gentle several dry needle sharps live needlestick sharps applicable patient due update updates other proper read other refresher attend cultural 30-day 3-month Berkeleyway-Berkeley.ca94704 follow-up 1-12 22-25mm 22-32mm 25-32mm Older o， ★ → > < …….………….…… ·ln uappon ， -···）， ， < · ………… > ， … ★ → unuuuu uo semus “ steady other other seated lish e nº | servº- D-17 Federal E-1 E-2 E-3 E-8 federal current recent 3-month-old vaccine-associated paralytic first sequential inactivated live current serious many Most adverse mild self-limited Serious such rare devastating re- ef- safe possible important parents/legal ob- jective dis- vaccine ad- common mild vac- standardized objective infor- adverse un- and/or informa- vaccines. intense prop- erly minor legal healthcare address con- parent/legal repre- mandatory pneumo- coccal vac- parent/legal available pneumococ- cal yellow typhoid vac- re- federal meningo- coccal mandatory local individual pro- other legal NCVIA-covered adminis- tered parent/legal representa- current available patient vaccine objective jour- www.vaccine ap- imperative current Most current recent available local www.cdc.gov/nip/publications/vis available several trans- more complete current orgate * www.vaccineinformation.org E-1 trivalent influenza effective pneumococcal relevant current legal representative such such relevant legal long-term relevant later single component other quali- minor incompetent visual oral permanent medical permanent medical permanent Current legal additional applicable camera-ready available available §300aa-26 available other E-2 current available single hard new available Spanish most Text compatible screen-reader available more French Armenian German Laotian Serbo-Croatian Bosnian covered appropriate informed tear-off technical informed infor- enough procedural oral substantive medical specific informed require- informed appropriate legal same legal legal other legal legal representative sure representative useful recommended adverse E-4 new final new adverse previous new illiterate visual oral unable least compatible screen available old obsolete adverse multiple identical different recently-dated valid current adverse adverse clinical likely |-T traditional difficult misleading standard reliable multi-syllable understood individual short bulleted long easy Fletch-Kincaid 10th useful several focus low racial ethnic native easy Which appropriate available meningococcal available own official own clinic other other prior E-6 legal present school- adolescent legal alternative signed signed medical permissible single entire such acceptable first legal representative complete possible approximate future accept- following additional initial legal original additional earlier next original additional medical additional additional significant adverse earlier adverse previous medical E-7 //www.cdc.gov/nip/publications/VIS/default.htm main º ſºn wis T- at-lance-vaccine El-tin-i-tº- sheet-produced center-for-o-º-º-control legal representative-both benefit-and-risk- and-tº- int-tº-letton- -given new -it- 1-poºl an- nºn- viss upcoming other nºt fºrmat El-ºn- recent upcoming Last in-ni- updated in-tº-hudian º Polic | |- Local main * º printable other languages- º text-only- A- printable screen-reader reader- accessible able audio screen-reader appendix Reportable F-2 F-9 national analyzes adverse most describe mild such serious adverse such important new VAERS Most vaccine other adverse significant adverse such unsure subsequent Reportable specified Reportable Table next VAERS adverse pre-addressed 1-800-822-7967 printable following //www.cdc.gov/nip/ more e-mail toll-free toll-free Reportable |- anaphylactic additional applicable See insert anaphylactic additional applicable insert additional T- anaphylactic applicable insert above applicable additional insert 7-30 viral immunodeficient applicable additional See insert type a- viral applicable additional additional anaphylactic above applicable See insert anaphylactic above applicable additional additional additional |- above applicable additional |Pneumococcal additional * Effective Reportable reportable 300aa-25 significant unexpected certain adverse mT Reportable Table anaphylactic anaphylactic severe lethal systemic allergic Most few airway laryngeal upper other peripheral e.g. nerve single peripheral central e.g. spinal nervous deep steady severe upper upper Sensory notable clinical Reportable encephalopathy such applicable such per- more severe less associated least less follow postictal older least least following significant mental medication confusional independent intracranial clinical least following clinical least greater absent painful absent other absent external familiar following clinical sig- nificant mental high-pitched unusual persistent inconsolable sufficient other first neurologic applicable least vaccina- normal neurologic encephalopathy residual neurologic subsequent encephalopathy preponder- chronic secondary genetic prenatal perinatal chronic encephalopathy metabolic structural genetic meta- bolic structural genetic Reportable Table chronic joint Medical objective joint Medical acute objective continuous more Medical < chronic Musculoskeletal such connective limited systemic systemic mixed connective fibromyal- degenerative infectious other direct immune metabolic endocrine dis- neuropathic inflammatory joint joint chronic ſº invasive bacterial sterile clinical invasive radiographic positive above invasive bacterial adverse first Reportable ºf www.vaers.org 1-877-721-0.366 Toll-Free Last Responsible different || adverse appropriate permanent above Adverse Relevant diagnostic Previous other Previous Other clinic unknown Pre-existing physician-diagnosed medical adverse Adverse prior applicable mtrſimm ] 300aa-25 Reportable other voluntary 20849-1100 more separate best essential possible such Reportable other serious other suspected adverse adverse legal adverse 09-20-0136 legal available available legal * front same SPECIFIC suspected adverse Such local general same UNKNOWN exact possible more adverse serious negative normal relevant abnormal other short ear pre-existing physician-diagnosed medical developmental neurologic suspected adverse previous more more prior additional onset less old no-fault traditional vaccine routine compensible individual vaccine-related physician medical special eligible special Compensable most non-compensable civil first more peti- anaphylactic 2-28 acute applicable antigen-containing anaphylactic acute applicable anaphylactic 0-4 e.g. 5-15 acute applicable virus-containing 7-42 acute above applicable virus-containing 7-30 immunodeficient 0-6 recipient acute applicable live non-immunodeficient recipient 0-30 immunodeficient 0-6 applicable viral non-immunodeficient recipient 0-30 immunodeficient 0-6 applicable acute applicable anaphylactic 0-4 acute above applicable antigen-containing anaphylactic acute above applicable applicable applicable applicable live oral rhesus-based 0-30 acute above applicable applicable new applicable routine Effective needle nasal trivalent more www.hrsa.gov/osp m appendix anaphylactic severe lethal systemic allergic reac- Most few airway laryngeal cardiovascular Other significant clinical following lower tract minimal spleen significant pathologic encephalopathy such applicable such more acute severe less associated least less postictal older least significant mental medication confusional independent intracranial clinical least following clinical least greater applicable absent painful absent other absent external familiar following clinical significant mental high-pitched unusual persistent inconsolable sufficient other first neurologic applicable least normal neurologic encephalopathy tº º wº residual neurologic subsequent evi- chronic secondary genetic prenatal perinatal fac- chronic encephalopathy infec- metabolic structural genetic metabolic structural genetic vaccine-related possible preponder- encephalopathy shall- entire medical con- myoclonic tonic-clonic grand simple complex partial move- chronic joint objective joint acute objective continuous more chronic Musculoskeletal such connective limited rheuma- systemic systemic mixed con- nective vascu- degenerative infectious other direct immune metabolic endocrine neuropathic inflammatory joint joint chronic upper divi- other peripheral e.g. nerve single peripheral spinal nervous deep steady severe shoul- upper weak- upper Sensory notable clinical present same opposite bilateral upper reflex physical nerve electromyographic consistent attributable brachial distinguishable con- peripheral multiple other peripheral central nervous cranial | serum less Thrombocytopenic other such previous lymphoproliferative congenital hemolytic uremic fungal Thrombocytopenic disseminated intravascular bacterial viral human antecedent clinical Seſ- logic normal increased normal Vaccine-strain viral specific monoclonal Vaccine-strain viral affected vaccine-strain sufficient specific vaccine-strain º * Vaccine-Preventable 1950-2003 20th 1962-2004 1950-2003 paralytic * ſ reportable Congenital other other invasive notifiable Final Reportable 1971-2002 Notifiable Reportable 1950-1970 Earlier respective Dec u tº > paralytic > > < est 1900-1998 Final Notifiable G-7 1962-2004 | |Heps3 * | * || || | || measles-containing 4-3-1 more more more measles-containing 4-3-1-3 more more more measles-containing more represent 2- year-old represent 19-35 month-old Different national 1986-1990 Most recent 19-35 717-721. H-1 H-21 H-40 1133-7. available H-3 H-5 H-14 H-17 public private local public private essential desirable medical public important national vac- cine-preventable vaccine several important preschool private primary critical disadvantaged such national preventive high important diminishing experience- ready vaccine-related inaccurate misleading many American American adolescent federal local professional 2001-02 medical public endorse- More inclusive many clinical mid-level nurse physician medical clerical primary useful public profes- minimum desirable current difficult little best clear concise necessary own adoles- nationwide feasible likely available other possible accepted Effective appropriate easy-to-understand appropriate vaccine Up-to-date accessible vaccine knowledgeable receive on-going many indicated pos- accurate complete accessible adverse accurate- aware separate due overdue Office- clinic-based per- community-based available primary recommended main primary such physical necessary primary primary other possible comprehensive primary routine well-care other other subsequent primary primary iden- well-care age-appropriate educational physical important sufficient vaccination-only available easier =- Out-of-pocket costs-including fees-should low possible patient low possible Free available public vac- reasonable local aware setting-private public-in recommended covered vaccine web www.cdc.gov/nip/wfc missed high preventive primary needed accepted due medical missed prior adverse deferral available harmonized available www.cdc.gov/nip/recs/child-schedule.htm other relevant medical Effective appropriate easy-to-understand sufficient adolescent known recommended hand-held adolescent federal vaccine-specific two-page necessary oral other appropriate address adolescent adverse medical necessary =-m 1-800-232-0233 Spanish latest available numerous other www.immunize.org national appropriate appropriate vaccine Summary available local vaccine undertake Further available 404-639-8222 Up-to-date accessible safe effective vaccine vac- adverse consistent up-to-date vaccine knowledgeable receive on-going knowledgeable receive vaccine recommended adverse appropriate other other specific responsibili- distance-based satellite web-based self-administered available many indicated possible same American American safe effective certain simulta- neous missed earlier earliest simultaneous accurate complete accessible standard accessible medical rapid federal 300aa-25 following medical primary primary local available accurate complete useful new hand-held pro- adolescent available adverse aware separate significant adverse follow- certain adverse medical possible aware no-fault routine aware separate brief | VAERS 1-800-822-7967 available 1-800-338-2382 other available //ftp.cdc.gov/pub/publications/mmum/rr/rr4618.pdf due overdue due overdue specific high medical previous more intensive due overdue patient profes- other automatic Office- clinic-based effective chart Effective low local community-based highest possible vaccine-preventable entire opti- vaccine-preventable high underserved Community-based public other such Special Supplemental serv- 19-35 20:28-31 vaccine 21:243-249 free physician public American medical 184-186 descriptive available American American Healthy Available www.health.gov/healthypeo- revised Physician American H-15 School-Based infectious adverse public private local governmental ex-officio valuable H-19 available American H-23 H-25 H-35 H-38 successful vaccine-preventable similar immune older younger high older younger high pneumococcal vac- susceptible routine vast vaccine-preventable average influenza influenza more other invasive invasive pneumococcal year. More due adults. young unpro- congenital older recommended safe effective available disease underutilized high certain racial/ethnic pneumococcal African Hispanic lower comprehensive nationwide vaccine-preventable dramatic current pneumococcal older annual pneumococcal national less high due medical behavioral environmental greater first more professional private specific improvement. adult nontraditional recent comprehensive previous evidence-based possible expert more available revised instruc- reminder/recall personal revised convenient desirable major professional public private adult neces- sary useful current additional available available Assess valid easy-to-understand document available simultaneous indicated accurate accessible due overdue Regular Patient-oriented community-based available recom- mended increased vaccine-preventable recommended meningococcal international Standard physical additional educational mate- appropriate patient/guardian vaccine con- sufficient Standard minimized patient low possible older patient private vacci- basic adequate Assess new initial annual medical lifestyle certain preventive pneumococcal influenza Standard valid valid invalid needless indicated prior adverse current valid invalid valid easy-to-understand known native possible most public private potential available other profes- ample address 1-800-232-2522 informed more Written available medical vaccine vaccine sched- adverse consistent CDC-recommended available significant adverse follow- medical aware encour- available 1-800-822-7967 no-fault compen- vaccine routine aware available 1-800-338-2382 separate Such brief Standard vaccine adverse Office appropriate other public authori- other medical more individu- Standard simultaneous indicated indicated safe effective Simultaneous administra- required missed adminis- combined pneumococcal same separate safe effective Standard accurate accessible standard accessible loca- medical rapid needed unnecessary medical primary such influenza paper-based record easier personal medical H-28 mº-m modifiable available available www.atpm.org/Immunization/whatworks.html immunized other first e.g. annual appropriate vaccina- available www.cdc.gov/nip/publications/ACIP-list.htm due overdue recall due overdue specific high med- ical more intensive º individual due overdue specific other specific general available available www.ahcpr.gov/ppip/postcard.pdf other insti- tutional enable non-physician such direct physician administrative such physician m available www.atpm.org/Immunization/whatworks.html Regular vaccination such per- other local Effective assessment low available available Patient-oriented community-based exam- other such extended other profes- local 1-28 respiratory syncytial 289:179-186 Active Available invasive pneumococcal antibiotic 1995-1997 invasive 1995-1998 285:1729-35 Available Available unpublished 1993-1997 greater equal 532-3 Healthy Early Available ww.cdc.gov/nchs/about/major/nhis/released Vaccine-Preventable 725-729 1133-7 1-13 Vaccine-preventable vacci- Physician American School-Based infectious adverse public private vac- local repre- governmental ex-offi- cio valuable public many professional social straightforward vital easy public much harder public important public Local public public governmental public other public voluntary community-based other public less essential public essential several national federal public public essential public overall public common public Healthy Healthy physical mental ten public public Table valuable organizational more promising essential general public regard- specific programmatic com- communications/social good other critical assess public nationwide public major 21st public essential essential public public broad complicated personal healthy individual personal unavailable competent public personal per- sonal population-based new innovative wº 2'- Special preventable major amongolder safe available Several low inadequate aware- hospital medical public private federal major public provider major clinical financial public private vaccine-preventable dis- vaccine-preventable new improved prac- international many inſec- tious ” disap- andfatal whoop- rare. indig- enous few congenital ru- sel- re- extraordinary influenzae attributable widespread congenital syn- vaccine-prevent- able constant unhesitating corolete corrºr-tree tre un 1994-Vol most vaccine-preventable strik- fewer vaccine-prevent- able compari- influ- pneumococcal hepa- many child- vaccine-preventable young Out- major such Vaccine-preventable re- main important costly hospi- more American com- lower several ad- much heavier dis- Table Several ex- limited per- general vaccine-preventable signifi- cant Second effi- several immuniza- selective universal different different Table individual larger child- child- statutory adult most communi- few private ne- private in- expensive free public most full most public avail- vaccina- responsible high best diffi- same im- More new pneumococcal vac- many new ini- American ſectious next mil- multifaceted influenza cost- immunization—The 1.-Reported Vaccine-Preventable –99.4 paralytic -100.0 * –99.7 1964-1965 -99.9 * ale reported available provisional tetanus vacane-associated reportable reportable Table infºuenz- < < Variable elderly immunocompromised lower targeted current different older potential additional annual * different * Japanese yellow appucable adultim- de- Vaccine-preventable dis- impose significant strong cost-effective. more un- prevented less first rec- Table general elderly high-risk immu- pneumococcal new under- vaccine-prevent- able clinical good organiza- vac- specific de- successful organized regular public se- vaccine-preventable essen- tial. elderly ap- severe hospital pneumococcal Few young sexual ac- Many un- clinical Educational public immuniza- admin- helpful older vaccinated. educa- tional phy- other wide- spread rec- riodic immu- better understand- administrative organiza- tional successful profes- sional more prac- tical appropriate better vaccine-preventable dis- ben- constitute easy vac- recom- educational espe- announce- popu- com- efficacious effective local public federal con- epidemiol- vaccine-preventable vaccine pro- Table infuerº- 18-24 x x x 25-64 x second entenng ºr postsecondary educational international vaccine-prevent- able Such vaccina- several mis- vac- vaccine-preventable due vac- high Most ad- wide principal general spe- cialized profession- administrative such such single respon- dif- devel- workable re- Such common as- other federal in- creased vaccine local com- provid- con- recommended administra- tive organizational regular stan- regular evalu- financial federal local involved adult less pneu- mococcal local unpublished pneumococcal vacci- elderly reim- end- renal influenza reim- pneumococ- cal pneu- mococcal reimbursement pro- adequate important adultimmunizationshould become annual influenza little ex- private adultim- organi- such bet- tra- ditional regulatory adult im- sufficient busi- subject gov- child- Similar reimburse administra- moni- iden- tified technical pro- vided financial other private providersfor indi- vidual adult cov- adult public oftective adequate • vaccine-preventable cºnical cost-oerºtºooº-ºººcinºn-soº insured national pro- adult immu- vaccine- preventable continu- them- capac- vac- effective efficient vac- clear un- epi- important per- local vaccine-preventable ex- timely ad- influenza current protective. ” under- hepati- pneumococcal inexpensive rapid Sur- essential economic vac- cine-preventable immuniza- constant swine influenza pro- vaccine sup- tested. economic vac- cine es- childhood vaccine-as- Al- costly better pneumococcal elderly pneumococcal little geographic great vac- other high-risk more surveil- vaccine-preventable local better diag- nosing recom- nation's current future peri- potential technical regulatory financial legal political adequate appropriate federal vaccine vaccine- related detailed specific high-risk condi- inspecific supportforpro- deliverywhere un- fol- pneumococcal influenzaimmunizationamong institution- illor older least pneumococcal influenza non- high-risk least high-risk antigen-positive least work- least intravenous-drugus- AsSUREADEQuATE bac- essential new improved vac- important vaccina- older immune responsive initial ef- clinical serious costly economic vaccine-preventable dis- adultim- cur- pneumococcal highlycost- effective other pre- inter- common elderly epi- vac- provid- arecentstudy greatest likely vaccinated. several new improved cold-adapted live pneumococcal vari- acellular new vaccine newer adju- epitope-based re- antigen rec- de- vaccine-pre- ventable dis- Current international dis- easessuch supple- infectious such formerSoviet antimicrobial-resistant many coun- paidrichdividendsintheworldwide eradi- new improved be- new vac- countries. new improved continued microbiologi- immunization—The cal vaccine-preventable immunocompromised aging de- better economic cur- future vaccine-preventable dis- immuniza- continued evi- current fu- recom- greater stud- new improved stable com- greater federal nongovernmen- tal professional associa- interna- tional 1992:3:27:1794-1800 Gen- eral recommen- teta- other Eradi- 10222-229 1989- 1992:43:451-463 congenital 1982267.2616-2620 univer- 1989,84779-784 el in- 1987-1993 Adverse fol- Reportable vaccine-preventable 43:57-60 1993.328:1252-1258 medical set- em- 77-725-726 complex sub- stantial immuni- less op- timal infectious im- optimal adverse reac- responsible non- produc- Na- im- elderly 1532106-2111 public preventable American Final vaccine demon- 1988-1992 f Healthy Clinical public pneumococcal elderly influenza vaccine missed influ- enza computer-generated influenza vac- alternative 1990.263:1218-122 Pneumococcal poly- 140-528–530 Comprehensive Mìn- 1986-1992 Russian toxigenic 501-503 drug-resistant pneumococcal immunization—The I-1 I-2 I-3 I-4 I-5 I-6 I-7 800-232-4636 800-CDC-INFO Spanish vaccine-preventable single vaccine-preventable related e-mail //www.cdc.gov/nip online such online vaccine latest downloadable other //www.cdc.gov/nipſed/curriculum/curric-brochure.htm online online viral reliable helpful informative • satellite current • periodic several immunization-related • toll-free • global international É Q- ready-to educational Other other professional most federal • Helpful more viral pºſſ many other useful free //www.immunize.org/catg.d/free.htm //www.immunize.org/catgidſp4060scr.pdf 11-19 old Takeim n settidn -i-i-º-º- //www.immunize.org/catg.c/p3039pof much practical e-mail new new hot • vaccine-preventable ſº- ſ/7 ºft Subject _- ºn fe f 35-minute latest Available Spanish different IMM-712 Other INAM-720 payable | 594-21 594-5933 authorized other global national other immunization- related Global //www-nt.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm “ selected routine Little PSD-IMM-A4 206-2044 562-7802 364-3276 661-2300 883-6015 691-6118 509-7945 ºf 739-2358 657-1463 586-8302 PHONE 334-4914 524-0967 746-6388 Chavez-Torres 233-7805 50319-0075 66612-1274 831-6292 296-6368 564-4760 PHONE 483-1909 287-8127 333-5893 Talebian 335-9855 676-5689 Vaccine-Preventable 08625-0369 576-7686 526-6892 444-2920 471-6426 684-8338 271-3850 588-7431 827-2898 12237-0627 27609-3811 58505-0200 10th 474-7381 676-2252 870-4824 328-1412 728-4279 271-6133 @ 731-3095 Lorraine 705-5513 I-II 685-6806 222-1442 898-0318 773-5509 741-3857 458-7288 794-9937 207-8882 538-9440 lable utah.gov 25301-3715 865-7701 786-0396 235-3590 PHONE 576-6418 558-1941 @ 267-9493 777-6001 Wells-Fahling GRANTEES 011-684-633-7223 011-684-633-5379 011-671-735-71.43 011-671-734-1475 248-4393 011-692-625-8457 011-692-625-3432 011-691-320-2619 011-691-320-5263 011-670-236-8733 011-670-234-8930 011-680-488-4804 011-680-488-3115 274-5619 777-8762 n < ſe * º § ©e sºvº 